

# ECTH 2018

24 - 26 October 2018

[ecth2018.org](http://ecth2018.org)



## ECTH 2018

European Congress on  
Thrombosis and Haemostasis

Marseille, France

# Download the ECTH 2018 app

Keep yourself up-to-date and carry the congress in your pocket.



- **Scientific programme**
- **Invited speakers**
- **All abstracts**
- **Networking events**
- **Partner information**
- **Floorplans**
- **Real-time congress alerts**



## **| Table of Contents**

<b>Networking events</b>	<b>4</b>
<b>General scientific information</b>	<b>6</b>
<b>Congress general information</b>	<b>7</b>
<b>Programme Wednesday 24 October</b>	<b>9</b>
<b>Programme Thursday 25 October</b>	<b>17</b>
<b>Programme Friday 26 October</b>	<b>45</b>
<b>Poster sessions overview</b>	<b>55</b>
<b>Poster information</b>	<b>57</b>
<b>Floor plans</b>	<b>75</b>
<b>Special symposia and Partners</b>	<b>79</b>

## Networking events

### Opening ceremony

Wednesday 24 October

17.45 - 18.30 hours

Auditorium

All delegates and sponsors are welcome to attend.

### Welcome reception

18.30 - 19.30 hours

Network area

### Poster reception

Thursday 25 October

17.00 - 18.30 hours

Poster session area

Take advantage of the guided sessions - choose the most interesting group and be on time.

### Controversial corner

Thursday 25 October

17.00 - 18.30 hours

Poster session area

During this engaging event, 8 speakers have 5 minutes each to make a controversial statement on topics related to Thrombosis and Haemostasis. We hope to see you there to debate and discuss your ideas on the topic.

### Congress dinner

Thursday 25 October

19.15 - 00.00 hours

Les Grandes Tables at Friche La Belle de Mai

*Price: € 60 per person*

The congress dinner of ECTH 2018 offers a great opportunity to meet and network with other experts in an informal setting, while tasting some local specialties from southern France. The walking dinner will take place in a unique space showcasing both industrial and contemporary aspects: Friche La Belle de Mai! At its restaurant, Les Grandes Tables, you will enjoy a variety of fresh seasonal products with a lively DJ setting the perfect atmosphere.

*Busses will depart at 18:45 from Palais des Congrès - Marseille Chanot*

*First busses will return as of 21:30 from the restaurant*

Tickets can be purchased for € 60 at the Service desk in the registration area.

### Sport activity

Friday 26 October

12.30 - 13.30 hours

Terrace on the 2nd floor

All delegates are invited to join a fun session and play pétanque on Friday. One of the most popular games in France, pétanque is played by throwing heavy balls as close as possible to a smaller target ball, while standing inside a circle with both feet on the ground. Join us on the 2nd floor on the terrace of Palais des Congrès- Marseille Chanot. Joining is free of charge.



## General information regarding the scientific programme

### Important notice for chairs and speakers

All chairs and speakers are kindly requested to be in the session room at least 15 minutes before the beginning of the session.

### Abstracts

All abstracts are listed in the online Abstract Book, available at the congress website and in the ECTH mobile application.

### EBAH CME accreditation

The programme of the 2nd European Congress on Thrombosis and Haemostasis has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH). The EBAH has approved this educational activity for a maximum number of 14 CME credits.

### Certificates of attendance

Certificates of attendance will be sent by email, shortly after the congress.

### Speaker Service Centre

The Speaker Service Centre (SSC) is located in room L'Escalette, located on the first floor. Speakers are requested to bring their presentations to the SSC on a USB stick at least 1 hour prior to the session starts. The use of your own laptop during your presentation is NOT possible.

### Opening hours of the SCC:

Wednesday	24 October	07.00 - 18.00 hours
Thursday	25 October	07.30 - 18.00 hours
Friday	26 October	07.30 - 13.30 hours

### Programme changes

The organisers cannot assume liability for any changes in the programme due to external or unforeseen circumstances.

## Congress general information

### Registration hours

The registration desk, located on the first floor, will be open on the following days:

Wednesday	24 October	07.00 - 18.00 hours
Thursday	25 October	07.30 - 18.00 hours
Friday	26 October	07.30 - 13.30 hours

### Services provided at the registration desks include:

Lost and Found

Tickets for sale for the Congress Dinner at the Service Desk.

### Badges

All participants will receive a personal badge upon registration. You are kindly requested to wear your name badge at all times, during scientific meetings and social gatherings. Only participants who are wearing their name badge will be admitted to the congress.

### Cloak room

A guarded cloak room is available on the first floor, next to the registration area and open on the following days:

Wednesday	24 October	07.00 - 19.30 hours
Thursday	25 October	07.30 - 18.30 hours
Friday	26 October	07.30 - 15.30 hours

### Catering

Food and beverages will be served in the Network area located on the first floor.

### Insurance

The congress organiser cannot accept responsibility for accidents that might occur. Delegates are encouraged to obtain travel insurance (medical, personal accident and luggage) in their home country prior to departure.

### Internet

Wifi is available in the congress related areas. The network name is: FREE\_WIFI\_CHANOT. There is no password required.

### Language

The official congress language is English. On Wednesday morning, the sessions will be in French, hosted by the French National Societies. No simultaneous translation is available.

### Staff

If you have any questions, the congress staff will be pleased to assist you.

## Notes

[illegible]

# Programme Day 1

## Wednesday 24 October

Programme at a Glance

- Plenary Session
- Bleeding
- Clotting
- Platelets
- Vessel Wall
- State of the Art
- Science, fast and furious
- French sessions
- Other Sessions
- Special Symposium

Programme  
Wednesday 24 October

	Auditorium	Callelongue	Endoume 1	Endoume 2
08:00 - 10:00	COMETH meeting	Master class INNOVTE	GFHT workshops	
10:00 - 10:30		Coffee break		
10:30 - 12:15	COMETH meeting	Master class INNOVTE	GFHT workshops	
12:15 - 13:15		Lunch break		
13:15 - 15:00	Compendium in bleeding disorders (endorsed by COMETH-GFHT)	Fibrinolysis : New therapeutic aspects (endorsed by GFHT-GHP-INNOVTE-SRMV)	Bleeding and platelet disorders (endorsed by the Club des megacaryocytes and GFHT)	
15:00 - 15:15		Short break		
15:15 - 16:15	Plenary Fake news, fake science			
16:15 - 17:15	Science, fast and furious			
17:15 - 17:45		Coffee break & poster viewing		
17:45 - 18:30	Opening ceremony			
18:30 - 19:30		Welcome reception		

Wednesday 24 October

**08.00 - 10.00**

**Hall: Auditorium**

## I COMETH meeting

**08.00 - 09.15**

Actualités - Mise au point:

Apport du NGS dans les syndromes hémorragiques inexpliqués,

Christophe Zawadzki, Lille, France

Thérapie Génique, Sandra Le quelle, Lyon, France

Emicizumab et autres, Antoine Rauche, Lille, France

**09.15 - 10.00**

Assemblée Générale de la COMETH

**08.00 - 10.00**

**Hall: Callelongue**

## I Master class INNOVTE

**08.00 - 09.00**

Thème 1

Méthodologie

Non inférieure, Laurent Bertoletti/ Silvy Laporte

Score de propension, Silvy Laporte/ Patrick Mismetti

**09.00 - 10.00**

Thème 2

Le bilan thrombophilie d'aujourd'hui et de demain, David Tregouet/

David Smadja

## Wednesday 24 October

**08.00 - 10.00**  
**Hall: Endoume 1**

### I GFHT workshops

- 08.00 - 11.00** Thème unique, Thrombophilie: quelles analyses biologiques? Pour quels patients? Dans quel but?
- 08.00 - 08.30** Accueil et présentation du projet: Pierre Morange et Yves Gruel
- 08.30 - 10.15** Réunion des groupes de travail  
Groupe de travail N°1: Quels malades explorer et pourquoi?
- La MTEV selon l'âge: confrontation d'avis d'un pédiatre, d'un gériatre et d'un interniste vasculaire
  - Thromboses insolites: lesquelles et quels facteurs de risque?
  - MTEV, grossesse, PMA et contraception (cela serait peut être bien d'ouvrir ensuite aux sociétés de Gynécologie et d'endocrinologie): spécificités et conséquences pour l'exploration
  - MTEV spontanée? MTEV provoquée? Pas si simple...  
Durée du traitement anticoagulant: la biologie ne sert à rien, OUI ou NON
- Groupe de travail N°2: Quels tests et comment?
- Les inhibiteurs de la coagulation: toujours trois, pas plus?
  - Les analyses génétiques: restreintes ou plus étendues?
  - L'hémostase: oui, mais aussi un peu d'immunologie et de biochimie...
  - Anticoagulants et exploration biologique des thromboses: Comment faire aujourd'hui?
- 10.15 - 10.30** **Coffee break**

## Wednesday 24 October

**10.30 - 12.15**  
**Hall: Auditorium**

### I COMETH meeting

- 10.30 - 11.15** Retour des travaux en partenariat avec la COMETH
- Groupes de travail
  - Etudes cliniques (APACHE ...)
  - Projets financés par la COMETH: avancée des travaux
- 11.15 - 12.15** Présentations orales de cas clinique juniors

**10.30 - 12.15**  
**Hall: Callelongue**

### I Master class INNOVTE

- 10.30 - 12.15** Thème 3  
Durée de traitement et scores, Francis Couturaud/ Olivier Sanchez

**10.30 - 12.15**  
**Hall: Endoume 1**

### I GFHT workshops

- 10.30 - 11.15** Restitution des groupes de travail et discussion
- 11.15 - 12.15** Assemblée Générale du GFHT
- 12.15 - 13.15** **Lunch break**

Wednesday 24 October

**13.15 - 15.00**  
**Hall: Auditorium**

## **Compendium in bleeding disorder (endorsed by COMETH GFHT)**

- 13.15 - 13.40** GFHT 1.1 – GASTROINTESTINAL BLEEDING IN WILLEBRAND DISEASE  
Sophie Susen, France
- 13.40 - 14.05** GFHT 1.2 – CONSTITUTIONAL DEFECTS IN FIBRINOGEN  
Aurélien Lebreton, France
- 14.05 - 14.30** GFHT 1.3 – THROMBOSIS PREVENTION IN HEMOPHILIACS UNDERGOING SURGERY: WHERE ARE WE TODAY?  
Yessim Dargaud, France
- 14.30 - 14.55** GFHT 1.4 – UNDERSTANDING ACQUIRED FACTOR X DEFICIENCIES  
Olivier Christophe, France

**13.15 - 15.00**  
**Hall: Callelongue**

## **Fibrinolysis: New therapeutic aspects (endorsed by GFHT-GIHP- INNOVTE-SFMV)**

- 13.15 - 13.45** GFHT 2.1 – IMPACT OF T-PA ON BRAIN FUNCTION  
Denis Vivien, France
- 13.45 - 14.15** GFHT 2.2 – ANTIFIBRINOLYTICS AND PERIOPERATIVE MANAGEMENT  
Paul Zufferey, France
- 14.15 - 14.45** GFHT 2.3 – NEW STRATEGIES FOR IMPROVING FIBRINOLYSIS IN VTE  
Gilles Pernod, France
- 14.45 - 15.00** Q&A

Wednesday 24 October

**13.15 - 15.00**  
**Hall: Endoume 1**

## **Bleeding and platelet disorders (endorsed by the Club des megacaryocytes and GFHT)**

- 13.15 - 13.45** GFHT 3.3 – TICAGRELOL REVERSAL  
Anne Godier, France
- 13.45 - 14.15** GFHT 3.4 – CALDAG-GEFI THE IGNITION SPARKLE OF PLATELET ACTIVATION  
Mattias Canault, France
- 14.15 - 14.45** GFHT 3.5 – BLEEDING AND INFLAMMATION  
Benoit Ho-Thin-Noé, France
- 14.45 - 15.00** Q&A
- 15.00 - 15.15** **Short break**

**15.15 - 16.15**  
**Hall: Auditorium**

## **I Plenary lecture**

- 15.15 - 16.15** FAKE NEWS, FAKE SCIENCE  
Frits Rosendaal, The Netherlands

Wednesday 24 October

**16.15- 17.15**

**Hall: Auditorium**

## **I Science, fast and furious**

**16.15 - 16.30**

SFF 1.1 – FREQUENCY AND CLINICAL IMPACT OF ANTI-PF4/HEPARIN ANTIBODIES IN PATIENTS TREATED WITH EXTRA-CORPOREAL MEMBRANE OXYGENATION.

Caroline Vayne, France

**16.30 - 16.45**

SFF 1.2 – ELTROMBOPAG (EPAG) IMPROVED PLATELET COUNTS WITH SIMILAR SAFETY IN PATIENTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): SUBGROUP ANALYSES OF A 2-YEAR, PHASE IV, OPEN-LABEL STUDY.

Raymond Wong, Hong Kong

**16.45 - 17.00**

SFF 1.3 – TARGETING PROTEASE NEXIN-1, A NATURAL ANTICOAGULANT, TO CONTROL BLEEDING IN HEMOPHILIA A.

Karen Aymonnier, France

**17.00 - 17.15**

SFF 1.4 – SLC44A2 DEFICIENT MICE EXHIBIT LESS SEVERITY OF THROMBOSIS IN A STENOSIS MODEL OF DVT.

Chrissta Maracle, The Netherlands

**17.15 - 17.45**

**Short break**

**17.45 - 18.30**

**Opening ceremony (Hall: Auditorium)**

**18.30 - 19.30**

**Welcome reception**

- Plenary Session
- Bleeding
- Clotting
- Platelets
- Vessel Wall
- State of the Art
- Science, fast and furious
- French sessions
- Other Sessions
- Special Symposium

# Programme Day 2

Thursday 25 October

	Auditorium	Callelongue	Endoune 1	Endoune 2
08:15 - 09:15	Venous Thrombosis	Platelets and Neutrophils	Inflammation	Von Willebrand Factor
09:15 - 09:30		Short break		
09:30 - 10:30	Novel Treatments	Oral Anticoagulation	ADAMTS13	Cancer and Thrombosis
10:30 - 11:00		Coffee break & poster viewing		
11:00 - 11:30	State of the Art Prediction of thrombosis	State of the Art Biochemical basis non-replacement therapy		
11:30 - 12:00	State of the Art Platelets as immune effectors	State of the Art Recent studies in haemophilia treatment		
12:00 - 12:15		Short break		
12:15 - 13:15	Special symposium (not part of main CME)	Special symposium (not part of main CME)	Special symposium (not part of main CME)	Special symposium (not part of main CME)
13:15 - 13:30		Short break		
13:30 - 14:30	Plenary NETs: The nuclear threat of inflammation			
14:30 - 15:15	Renal disease and thrombosis	NETs	Platelets	Acquired platelet impairment
15:15 - 15:45		Coffee break & poster viewing		
15:45 - 17:00	Thrombosis: novel antithrombotic treatments	Platelets: new antiplatelet agents	Bleeding: hemophilia treatment: the next step	Assays: New treatments, new assays
17:00 - 18:30		Poster reception & poster viewing		
19:15 - 00:00		Congress Dinner: Les Grandes Tables at Friche La Belle de Mai (offsite)		

Programme  
Thursday 25 October



Thursday 25 October

**08.15 - 09.15**

**Hall: Auditorium**

## **Oral Communications: Venous Thrombosis**

**08.15 - 08.30**

OS 1.1 – VALIDATION OF A PROFILE OF 6 MIRNAS AS PREDICTOR OF EARLY INCIDENTAL POST-SURGICAL PULMONARY EMBOLISM IN GLIOMA PATIENTS.  
Álvaro Fernández-Pardo, Spain

**08.30 - 08.45**

OS 1.2 – THE ROLE OF STROKE AS A TRIGGER FOR INCIDENT VENOUS THROMBOEMBOLISM: RESULTS FROM A CASE-CROSSOVER STUDY.  
Vania Morelli, Norway

**08.45 - 09.00**

OS 1.3 – ASSOCIATION OF NEUTROPHIL EXTRACELLULAR TRAPS MARKERS AND VENOUS THROMBOEMBOLISM. RESULTS OF RETROVE PROJECT.  
Marc Arus, Spain

**09.00 - 09.15**

OS 1.4 – B LYMPHOCYTES AND ENDOTHELIAL DYSFUNCTION PROMOTE DVT. ECTH-244  
Catherine Lemarie, Canada

Thursday 25 October

**08.15 - 09.15**

**Hall: Callelongue**

## I Platelets and Neutrophils

**08.15 - 08.30**

OS 2.1 – HLA VARIANT RS6903608 IS ASSOCIATED WITH DISEASE ONSET AND RELAPSE OF IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA.

Ilaria Mancini, Italy

**08.30 - 08.45**

OS 2.2 – NEUTROPHILS PROTHROMBOTIC CHARACTERISTICS DURING MYELOPROLIFERATIVE NEOPLASMS.

Chloé James, France

**08.45 - 09.00**

OS 2.3 – CAPLACIZUMAB FOR ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA – RESULTS OF THE PHASE 3 HERCULES STUDY.

Flora Peyvandi, Italy

**09.00 - 09.15**

OS 2.4 – NEUTROPHIL-ENDOTHELIAL CELL INTERACTIONS DETERMINE THE REGULATION OF NEUTROPHIL ACTIVITIES BY PLATELETS.

Véronique Ollivier, France

Thursday 25 October

**08.15 - 09.15**

**Hall: Endoume 1**

## I Inflammation

**08.15 - 08.30**

OS 3.1 – COMPLEMENT ACTIVATION ASSESSED BY TERMINAL COMPLEMENT COMPLEX AND FUTURE RISK OF VENOUS THROMBOEMBOLISM.

Ina Isabella Høiland, Norway

**08.30 - 08.45**

OS 3.2 – DETECTION OF DIFFERENT FIBRINOLYSIS PATTERNS OF PLASMINOGEN MUTANT PROTEINS IN PATIENTS WITH LIGNEOUS CONJUNCTIVITIS ASSOCIATED TO INHERITED PLASMINOGEN DEFICIENCY: IMPACT ON CLINICAL OUTCOME.

Marie-Charlotte Bourrienne, France

**08.45 - 09.00**

OS 3.3 – THE DIFFERENTIAL ROLE OF PLATELETS AND FIBRIN IN ADHESION ON INFLAMED AND DAMAGED VALVES IN A NEW MOUSE MODEL OF EARLY STAPHYLOCOCCUS AUREUS ENDOCARDITIS.

Severien Meyers, Belgium

**09.00 - 09.15**

OS 3.4 – NEUTROPHIL EXTRACELLULAR TRAPS ARE ASSOCIATED WITH THE PATHOGENESIS OF DIFFUSE INTRA-ALVEOLAR HEMORRHAGE IN MURINE LUPUS.

Pierre-André Jarrot, France

Thursday 25 October

**08.15 - 09.15**

**Hall: Endoume 2**

## I Von Willebrand Factor

**08.15 - 08.30**

OS 4.1 – VON WILLEBRAND FACTOR DEFICIENCY DOES NOT INFLUENCE ANGIOTENSIN II-INDUCED ABDOMINAL AORTIC ANEURYSM FORMATION IN MICE.

Irina Portier, Belgium

**08.30 - 08.45**

OS 4.2 – HNA-3A EXPRESSED BY CTL-2 IS A CRUCIAL EPITOPE FOR NEUTROPHIL ADHESION AND ACTIVATION ON VWF.

Gaia Zirka, France

**08.45 - 09.00**

OS 4.3 – THE ROLE OF VON WILLEBRAND FACTOR IN EXPERIMENTAL MALARIA-ASSOCIATED ACUTE RESPIRATORY DISTRESS SYNDROME.

Sirima Kraisin, Belgium

**09.00 - 09.15**

OS 4.4 – THE VWF-GPIB INTERACTION MEDIATES THROMBO-INFLAMMATION IN EXPERIMENTAL STROKE VIA RECRUITMENT OF MONOCYTES, NEUTROPHILS AND T-CELLS TO THE BRAIN.

Frederik Denorme, Belgium

**09.15 - 09.30**

**Short break**

Thursday 25 October

**09.30 - 10.30**

**Hall: Auditorium**

## Oral Communications: Novel Treatments

**09.30 - 09.45**

OS 5.1 – CLEAVAGE OF ANTI-PF4/H IGG ANTIBODIES BY IDES, AND POTENTIAL BENEFIT IN THE TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA.

Jerome Rollin, France

**09.45 - 10.00**

OS 5.2 – GENERATION OF LLAMA-DERIVED SINGLE-DOMAIN ANTIBODIES DIRECTED AGAINST ANTICOAGULANT PROTEIN S.

François Saller, France

**10.00 - 10.15**

OS 5.3 – FACTOR VIII ACTIVITY AND ANTI-FVIII INHIBITOR TITER DETERMINATION ON PATIENTS TREATED WITH HEMLIBRA® (EMICIZUMAB): WHICH FVIII ASSAY USED?

Corentin Achard, France

**10.15 - 10.30**

OS 5.4 – SEARCH FOR ANTITHROMBIN CHEMICAL INHIBITORS AS AN ORAL TREATMENT FOR HEMOPHILIA.

Elsa Bianchini, France

Thursday 25 October

**09.30 - 10.30**

**Hall: Callelongue**

## I Oral Anticoagulation

**09.30 - 09.45**

OS 6.1 – VITAMIN K ANTAGONIST (VKA) VERSUS DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH CURRENTLY WELL CONTROLLED VKA FOR NON-VALVULAR ATRIAL FIBRILLATION: A RANDOMISED CONTROLLED PILOT TRIAL.

Jasper van Miert, The Netherlands

**09.45 - 10.00**

OS 6.2 – PERIOPERATIVE MANAGEMENT IN PATIENTS USING VITAMIN K ANTAGONISTS: A COHORT STUDY.

Louise Burggraaf, The Netherlands

**10.00 - 10.15**

OS 6.3 – NEUTRALISATION OF NON-VITAMIN K ANTICOAGULANTS BY 2MACROGLOBULIN-TRAPPED FACTOR XA.

Georges Jourdi, France

**10.15 - 10.30**

OS 6.4 – TARGETED SUBSTITUTION AT THE S4 SUBSITE OF HUMAN FACTOR X INFERS RESISTANCE TO THE DIRECT FACTOR XA INHIBITORS.

Mark Schreuder, The Netherlands

Thursday 25 October

**09.30 - 10.30**

**Hall: Endoume 1**

## I ADAMTS13

**09.30 - 09.45**

OS 7.1 – INHIBITING ADAMTS13 ACTIVITY PREVENTS THE LOSS OF HIGH MOLECULAR WEIGHT VON WILLEBRAND FACTOR MULTIMERS IN IN VITRO LEFT VENTRICULAR ASSIST DEVICES.

Shannen Deconinck, Belgium

**09.45 - 10.00**

OS 7.2 – CRYSTAL STRUCTURE AND ALLOSTERIC ACTIVATION OF ADAMTS13.

James Crawley, United Kingdom

**10.00 - 10.15**

OS 7.3 – OPEN ADAMTS13 CONFORMATION IN IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA IS INDUCED BY ANTI-ADAMTS13 AUTOANTIBODIES AND CORRESPONDS WITH AN ONGOING ADAMTS13 PATHOLOGY.

Elien Roose, Belgium

**10.15 - 10.30**

OS 7.4 – ADAMTS13 PEPTIDE PRESENTATION IN ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA.

Johana Hrdinova, The Netherlands

Thursday 25 October

**09.30 - 10.30**

**Hall: Endoume 2**

## I Cancer and Thrombosis

- 09.30 - 09.45** OS 8.1 – BIOLOGICAL PRO-COAGULANT AND PRO-INFLAMMATORY EFFECT OF INTERFERON ALPHA IN MYELOPROLIFERATIVE NEOPLASMS.  
Nadine Ajzenberg, France
- 09.45 - 10.00** OS 8.2 – ANALYSIS OF MICROVESICLE-MEDIATED THROMBOSIS IN CRISPR/ CAS9-MEDIATED TISSUE FACTOR KNOCKOUT BREAST CANCER CELLS.  
Araci M. R. Rondon, The Netherlands
- 10.00 - 10.15** OS 8.3 – PARADOXICAL ROLES OF PLATELETS IN COLORECTAL CANCER.  
Léa Plantureux, France
- 10.15 - 10.30** OS 8.4 – INCREASED INCIDENCE OF CANCER IN THE FOLLOW-UP OF OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: THE NOHA-K OBSERVATIONAL STUDY.  
Jean-Christophe Gris, France
- 10.30 - 11.00** **Coffee break & poster viewing**

Thursday 25 October

**11.00 - 12.00**

**Hall: Auditorium**

## I State of the Art

- 11.00 - 11.30** SOA 1.1 – PREDICTION OF THROMBOSIS  
Suzanne Cannegieter, The Netherlands
- 11.30 - 12.00** SOA 2.1 – PLATELETS AS IMMUNE EFFECTORS  
Steffen Massberg, Germany

**11.00 - 12.00**

**Hall: Callelongue**

## I State of the Art

- 11.00 - 11.30** SOA 1.2 – BIOCHEMICAL BASIS NON-REPLACEMENT THERAPY  
Peter Lenting, France
- 11.30 - 12.00** SOA 2.2 – RECENT STUDIES IN HEMOPHILIA TREATMENT  
Carmen Escuriola-Ettingshausen, Germany
- 12.00 - 12.15** **Short break**

**13.30 - 14.30**

**Hall: Auditorium**

## I Plenary lecture

- 13.30 - 14.30** NETs: THE NUCLEAR THREAT OF INFLAMMATION  
Denisa Wagner, United States of America

Thursday 25 October

**14.30 - 15.15**  
**Hall: Auditorium**

## Oral communications: Renal Disease and Thrombosis

- 14.30 - 14.45** OS 9.1 – FREQUENCY AND PROGNOSTIC IMPACT OF ACUTE KIDNEY INJURY IN PATIENTS WITH PULMONARY EMBOLISM. DATA FROM THE RIETE REGISTRY.  
Martin Murgier, France
- 14.45 - 15.00** OS 9.2 – COMPARISON OF TWO DIFFERENT PROPHYLACTIC REGIMENS FOR THE PREVENTION OF ARTERIOVENOUS FISTULA THROMBOSIS IN PATIENTS WITH END STAGE RENAL DISEASE.  
Gorana Mitic, Serbia
- 15.00 - 15.15** OS 9.3 – ARYL HYDROCARBON RECEPTOR-RELATED MECHANISMS OF ENDOTHELIAL TISSUE FACTOR INDUCTION BY THE UREMIC TOXIN INDOLE-3 ACETIC ACID.  
Tawfik Addi, Algeria

Thursday 25 October

**14.30 - 15.15**  
**Hall: Callelongue**

## I NETs

- 14.30 - 14.45** OS 10.1 – MIR-146A CONTRIBUTES TO ARTERIAL THROMBOSIS DEVELOPMENT THROUGH REGULATING NEUTROPHILS EXTRACELLULAR TRAPS (NETS) FORMATION.  
Ana Belén Arroyo Rodríguez, Spain
- 14.45 - 15.00** OS 10.2 – NOVEL PLATELET-NEUTROPHIL INTERACTION VIA ACTIVATED IIBSS3 MEDIATES NETOSIS UNDER FLOW.  
James Crawley, United Kingdom
- 15.00 - 15.15** OS 10.3 – INHIBITION OF PROTEIN Z-DEPENDENT PROTEASE INHIBITOR BY NEUTROPHIL ELASTASE MAY PROMOTE PROCOAGULANT ACTIVITY OF NEUTROPHIL EXTRACELLULAR TRAPS.  
Elsa Bianchini, France
- 15.15 - 15.45** **Coffee break & poster viewing**

Thursday 25 October

**14.30 - 15.15**  
**Hall: Endoume 1**

## I Platelets

- 14.30 - 14.45** OS 11.1 – PLATELET LAMELLIPODIA FORMATION IS NOT REQUIRED FOR THROMBUS FORMATION AND STABILITY.  
Yvonne Schurr, Germany
- 14.45 - 15.00** OS 11.2 – CRITICAL ROLE OF PLATELETS DURING LUNG FIBROSIS.  
Yacine Boulaftali, France
- 15.00 - 15.15** OS 11.3 – EFFECT OF PLATELET-SPECIFIC PROTEIN S DEPLETION IN MURINE HAEMOSTASIS.  
Pablo García de Frutos, Spain

**14.30 - 15.15**  
**Hall: Endoume 2**

## I Acquired Platelet Impairment

- 14.30 - 14.45** OS 12.1 – SHEDDING OF PLATELET ADHESION RECEPTORS GPIB AND GPVI UNDER CONTINUOUS-FLOW MECHANICAL CIRCULATORY SUPPORT.  
Antoine Rauch, France
- 14.45 - 15.00** OS 12.2 – RIVAROXABAN AND APIXABAN REDUCE THROMBIN-DEPENDENT PLATELET AGGREGATION.  
Juraj Sokol, Slovakia
- 15.00 - 15.15** OS 12.3 – PLATELET FUNCTION DURING EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) IN ADULT PATIENTS.  
Camilla Mains Balle, Denmark
- 15.15 - 15.45** **Coffee break & poster viewing**

Thursday 25 October

**15.45 - 17.00**  
**Hall: Auditorium**

## Invited integrated symposium: Thrombosis; novel antithrombotic treatments

- 15.45 - 16.05** IIS 1.1 – NOVEL WAYS TO INHIBIT TAFIA IN THROMBOTIC DISORDERS.  
Michael A. Grosso, United States of America
- 16.05 - 16.25** IIS 1.2 – TARGETING THE INTRINSIC COAGULATION PATHWAY WITH ANTISENSE TECHNOLOGY.  
Brett Monia, United States of America
- 16.25 - 16.45** IIS 1.3 – ADHERENCE AND PERSISTENCE ON DOACS.  
Willem Lijfering, The Netherlands
- 16:45 - 17:00** Q&A

**15.45 - 17.00**  
**Hall: Callelongue**

## Platelets: new antiplatelet agents

- 15.45 - 16.05** IIS 2.1 – TOWARDS A NEW APPROACH FOR INHIBITING P2Y12 RECEPTORS.  
Markus Riederer, Switzerland
- 16.05 - 16.25** IIS 2.2 – GPVI: DEVELOPMENT OF ACT017, A THERAPEUTIC ANTIBODY  
Martine Jandrot-Perrus, France
- 16.25 - 16.45** IIS 2.3 – POTENTIAL NEW ANTITHROMBOTIC AGENTS TARGETING PLATELET INTRACELLULAR PROTEINS.  
Jonathan Gibbens, United Kingdom
- 16:45 - 17:00** Q&A

Thursday 25 October

**15.45 - 17.00**

**Hall: Endoume 1**

## **Bleeding: hemophilia treatment: the next step**

- 15.45 - 16.00** IIS 3.1 – SAFETY OF NOVEL NON REPLACEMENT THERAPIES IN COMBINATION WITH FVIII OR BYPASSING AGENTS?  
Johannes Oldenburg, Germany
- 16.00 - 16.15** IIS 3.2 – OPPORTUNITIES AND CHALLENGES IN CLINICAL TRIAL DESIGNS FOR HAEMOPHILIA GENE THERAPIES.  
Benjamin Kim, United States of America
- 16.15 - 16.30** IIS 3.3 – PRECLINICAL EFFICACY AND SAFETY OF SERPINPC  
Jim Huntington, United Kingdom
- 16.30 - 16.45** IIS 3.4 – EUROPEAN PATIENT ORGANIZATION (EHC) PATIENTS POSITION WITH REPLACEMENT AND NON REPLACEMENT THERAPIES IN HEMOPHILIA. WHAT THEY WANT TO KNOW?  
Brian O'Mahony, Ireland
- 16.45 - 17.00** Q&A

Thursday 25 October

**15.45 - 17.00**

**Hall: Endoume 2**

## **Assays: new treatments, new assays**

- 15.45 - 16.00** IIS – 4.1 NEW DRUGS NEW ASSAYS  
Cristina Novembrini, Italy
- 16.00 - 16.15** IIS 4.2 – DETECTION OF LUPUS ANTICOAGULANTS IN DOAC -TREATED PATIENTS  
Gary Moore, United Kingdom
- 16.15 - 16.30** IIS 4.3 – MEASUREMENTS/PLATELET REACTIVITY TESTING.  
Yves Gruel, France
- 16.30 - 16.45** IIS 4.4 – ADAMTS13: A FAST NEW ASSAY FOR DIAGNOSIS OF ACUTE TTP  
Maribel Mirabet, Spain
- 16.45 - 17.00** Q&A
- 17.00 - 18.30** **Poster reception**



Thursday 25 October

**17.30 - 18.30**

**Hall: Poster Sessions Area**

## I Poster Session: Vessel wall

- 17.30 - 17.40** BOARD NO 1: PS 1.1 – NETS CAN HELP TO ESTIMATE THE THROMBOTIC RISK IN BILIOPANCREATIC CANCER PATIENTS AT DIAGNOSIS.  
Álvaro Fernández-Pardo, Spain
- 17.40 - 17.50** BOARD NO 2: PS 1.2 – PLASMA LEVELS OF PROTEINS WITH ENDOTHELIUM ENRICHED EXPRESSION AND RISK OF VENOUS THROMBOEMBOLISM - A NESTED CASE-CONTROL STUDY.  
Maria Jesus Iglesias, Sweden
- 17.50 - 18.00** BOARD NO 3: PS 1.3 – THE ROLE OF COAGULATION FACTORS AND PLATELETS ON MICROVASCULAR INTEGRITY IN ATRIAL FIBRILLATION: IMPACT OF NOACS.  
Sophie Dolleman, The Netherlands
- 18.00 - 18.10** BOARD NO 4: PS 1.4 – ENDOTHELIAL CELLS AND NEUTROPHILS DEPENDENT, PLATELETS AND NETS-INDEPENDENT ARE INVOLVED IN ACTIVATION OF THE BLOOD COAGULATION CASCADE LEADING TO THROMBUS FORMATION FOLLOWING A LASER-INDUCED INJURY.  
Estelle Carminita, France
- 18.10 - 18.20** BOARD NO 5: PS 1.5 – FREQUENCY AND CHARACTERISTICS OF ATRIAL APPENDAGES THROMBI IN ATRIAL FIBRILLATION PATIENTS TREATED WITH WARFARIN OR DABIGATRAN.  
Oksana Kalashnykova, Ukraine
- 18.20 - 18.30** BOARD NO 6: PS 1.6 – DIRECT INHIBITION OF FACTOR XA BY RIVAROXABAN IS CARDIOPROTECTIVE IN RATS VIA A CYTOPROTECTIVE EFFECT ON CARDIOMYOCYTES.  
Sophie Guillou, France

Thursday 25 October

**17.30 - 18.30**

**Hall: Poster Sessions Area**

## I Bleeding 1

- 17.30 - 17.40** BOARD NO 7: PS 2.1 – THE PHARMACOKINETIC PROPERTIES OF FACTOR IX CAN BE IMPROVED USING GENETIC FUSION TO FACTOR XIII-B SUBUNIT.  
Sandra Le Quellec, France
- 17.40 - 17.50** BOARD NO 8: PS 2.2 – EMICIZUMAB PROPHYLAXIS ADMINISTERED ONCE-WEEKLY OR EVERY TWO WEEKS PROVIDES EFFECTIVE BLEED PREVENTION IN PERSONS WITH HEMOPHILIA A (PWHA) WITHOUT INHIBITORS – RESULTS FROM THE PHASE III HAVEN 3 STUDY.  
Claude Négrier, France
- 17.50 - 18.00** BOARD NO 9: PS 2.3 – REVISED PHARMACOKINETIC OF BENEFIX.  
Brigitte Tardy, France
- 18.00 - 18.10** BOARD NO 10: PS 2.4 – MULTICENTER PHARMACOKINETIC EVALUATION OF RFVIII-FC (ELOCTA®) IN 'REAL LIFE' AND COMPARISON WITH NON-EXTENDED HALF-LIFE FVIII CONCENTRATES.  
Claire Pouplard, France
- 18.10 - 18.20** BOARD NO 11: PS 2.5 – EFFICACY AND SAFETY OF HFVIII/VWF CONCENTRATE (VONCENTO®) IN PATIENTS WITH VON WILLEBRAND DISEASE (VWD) REQUIRING SURGICAL PROCEDURES: THE FRENCH EXPERIENCE.  
Lucia Rugeri, France
- 18.20 - 18.30** BOARD NO 12: PS 2.6 – MANAGEMENT AND OUTCOME OF BLEEDING COMPLICATIONS IN PATIENTS TREATED WITH DIRECT ORAL ANTICOAGULANTS.  
Roisin Bavalia, The Netherlands

Thursday 25 October

**17.30 - 18.30**

**Hall: Poster Sessions Area**

## I Bleeding 2

- 17.30 - 17.40** BOARD NO 13: PS 3.1 – INHIBITING ADAMTS13 IN A PRECLINICAL OVINE LEFT VENTRICULAR ASSIST DEVICE MODEL DOES NOT RESCUE THE LOSS OF HIGH MOLECULAR WEIGHT VON WILLEBRAND FACTOR MULTIMERS.  
Shannen Deconinck, Belgium
- 17.40 - 17.50** BOARD NO 14: PS 3.2 – NOVEL APPROACHES TO THE DIAGNOSIS AND CLASSIFICATION OF ANTI-FXIII ALLO-, AND AUTOANTIBODIES.  
László Muszbek, Hungary
- 17.50 - 18.00** BOARD NO 15: PS 3.3 – HIGH SOLUBLE THROMBOMODULIN IS ASSOCIATED WITH AN INCREASED RISK FOR MAJOR BLEEDING DURING TREATMENT WITH ORAL ANTICOAGULANTS: A CASE-COHORT STUDY.  
Myrthe Toorop, The Netherlands
- 18.00 - 18.10** BOARD NO 16: PS 3.4 – THE EFFECT OF DIFFERENT PROPHYLAXIS REGIMENS ON FIBRIN GEL STRUCTURE IN PATIENTS WITH SEVERE HEMOPHILIA A.  
Irena Djunic, Serbia
- 18.10 - 18.20** BOARD NO 17: PS 3.5 – REDUCED CLOT FIRMNESS MAY CONTRIBUTE TO BLEEDING PHENOTYPE IN PATIENTS WITH MILD BLEEDING DISORDERS.  
Caroline Veen, The Netherlands
- 18.20 - 18.30** BOARD NO 18: PS 3.6 – GENETICS AND HEMOSTATIC POTENTIAL IN HEMOPHILIA A PATIENTS WITH A DISCREPANCY BETWEEN ONE-STAGE AND CHROMOGENIC ASSAYS: A CROSS-SECTIONAL STUDY FROM HEMOPHILIA CENTERS IN STOCKHOLM AND BELGRAD.  
Annelie Straifors, Sweden

Thursday 25 October

**17.30 - 18.30**

**Hall: Poster Sessions Area**

## I Bleeding 3

- 17.30 - 17.40** BOARD NO 19: PS 4.1 – SPORTS PARTICIPATION AND PHYSICAL ACTIVITY IN PATIENTS WITH VON WILLEBRAND DISEASE.  
Ferdows Atiq, The Netherlands
- 17.40 - 17.50** BOARD NO 20: PS 4.2 – PLATELET COUNT AND RISK OF MAJOR BLEEDING AT VENOUS THROMBOEMBOLISM DIAGNOSIS.  
Håkon Sandbukt Johnsen, Norway
- 17.50 - 18.00** BOARD NO 21: PS 4.3 – DISCREPANCY BETWEEN ONE-STAGE CLOTTING AND CHROMOGENIC SUBSTRATE FACTOR IX ASSAYS IN HEMOPHILIA B PATIENTS: A CROSS-SECTIONAL STUDY FROM STOCKHOLM HEMOPHILIA CENTER.  
Maria Bruzelius, Sweden
- 18.00 - 18.10** BOARD NO 22: PS 4.4 – A NOVEL, COST EFFECTIVE LATERAL FLOW IMMUNOASSAY (LFIA) TECHNIQUE FOR THE DIAGNOSIS OF SEVERE VON WILLEBRAND DISEASE (VWD). ECTH-401  
Priyanka Kasatkar, India
- 18.10 - 18.20** BOARD NO 23: PS 4.5 – BLEEDING IN SUBJECTS WITH CONGENITAL FXI DEFICIENCY EXPOSED TO RISK SITUATIONS: ANTICOAGULANT TREATMENTS AND GYNECOLOGICAL AND OBSTETRICAL COMPLICATIONS. RESULTS FROM THE REAL WORLD.  
Carlos Bravo-Perez, Spain
- 18.20 - 18.30** BOARD NO 24: PS 4.6 – DEVELOPMENT OF THE FIRST POINT-OF-CARE TEST SELECTIVE OF THE DIRECT ORAL ANTICOAGULANT APIXABAN FOR EMERGENCY ASSESSMENT OF COAGULATION.  
Philippe Ohlmann, France

Thursday 25 October

**17.30 - 18.30**

**Hall: Poster Sessions Area**

## I Clotting 1

- 17.30 - 17.40** BOARD NO 25: PS 5.1 – PREVALENCE AND CLINICAL FEATURES OF A DELAYED OR MISSED DIAGNOSIS OF PULMONARY EMBOLISM: A SWEDISH CROSS-SECTIONAL STUDY FROM EMERGENCY DEPARTMENT VISITS.  
Astrid Koorti Kroon, Sweden
- 17.40 - 17.50** BOARD NO 26: PS 5.2 – DIETARY INTAKE OF MARINE N-3 FATTY ACIDS IS ASSOCIATED WITH LOWERED RISK OF INCIDENT VTE.  
Trond Isaksen, Norway
- 17.50 - 18.00** BOARD NO 27: PS 5.3 – CHARACTERIZATION OF DISEASE PRESENTATION AND TREATMENT OUTCOMES IN ATTP PATIENTS WITH INITIAL OR RECURRENT DISEASE DURING THE PHASE III HERCULES TRIAL OF CAPLACIZUMAB.  
Flora Peyvandi, Italy
- 18.00 - 18.10** BOARD NO 28: PS 5.4 – OBESE PATIENTS TREATED WITH APIXABAN AND RIVAROXABAN FOR VENOUS THROMBOEMBOLISM: A PILOT STUDY.  
Isabelle Gouin-Thibault, France
- 18.10 - 18.20** BOARD NO 29: PS 5.5 – RED CELL DISTRIBUTION WIDTH AND RISK OF ATRIAL FIBRILLATION AND SUBSEQUENT THROMBOEMBOLISM. THE TROMSØ STUDY.  
Erin Mathiesen Hald, Norway
- 18.20 - 18.30** BOARD NO 30: PS 5.6 – HIV INFECTION AND RISK OF RECURRENT VENOUS THROMBOEMBOLISM: A COMMUNITY-BASED COHORT STUDY.  
James Francis Borjas Howard, The Netherlands

Thursday 25 October

**17.30 - 18.30**

**Hall: Poster Sessions Area**

## I Clotting 2

- 17.30 - 17.40** BOARD NO 31: PS 6.1 – THE PSEUDONAJA TEXTILIS FACTOR VA A2 DOMAIN RETAINS FUNCTIONAL INTEGRITY FOLLOWING ACTIVATED PROTEIN C-MEDIATED PROTEOLYSIS.  
Mark Schreuder, The Netherlands
- 17.40 - 17.50** BOARD NO 32: PS 6.2 – A NOVEL ADAMTS13 CONFORMATION ELISA SHOWS CONFORMATIONAL ACTIVATION OF RAT ADAMTS13 WITH EXPOSURE OF CRYPTIC EPITOPES IN VITRO.  
Charlotte Dekimpe, Belgium
- 17.50 - 18.00** BOARD NO 33: PS 6.3 – CYTOSOLIC LOCALIZATION OF SMALL ANTITHROMBINS CAUSED BY A NEW MUTATION AFFECTING THE INITIATION CODON IN A LARGE THROMBOPHILIC FAMILY. BIOINFORMATIC ANALYSIS OF MUTATIONS AFFECTING INITIATION CODONS.  
María Eugenia de La Morena-Barrio, Spain
- 18.00 - 18.10** BOARD NO 34: PS 6.4 – MANNOSE-BINDING LECTIN-ASSOCIATED SERINE PROTEASE-1 (MASP-1) OF THE COMPLEMENT SYSTEM IS ASSOCIATED WITH DISSEMINATED INTRAVASCULAR COAGULATION IN SEPTIC SHOCK PATIENTS.  
Julie Brogaard Larsen, Denmark
- 18.10 - 18.20** BOARD NO 35: PS 6.5 – ANTI-CUB1 OR ANTI-SPACER ANTIBODIES THAT INCREASE ADAMTS13 ACTIVITY ACT BY ALLOSTERICALLY ENHANCING METALLOPROTEASE DOMAIN FUNCTION.  
An-Sofie Schelpe, Belgium
- 18.20 - 18.30** BOARD NO 36: PS 6.6 – STRUCTURAL FEATURES OF ACUTE ISCHEMIC STROKE THROMBI.  
Senna Staessens, Belgium

Thursday 25 October

**17.30 - 18.30**

**Hall: Poster Sessions Area**

## I Clotting 3

- 17.30 - 17.40** BOARD NO 37: PS 7.1 – PHENOTYPIC AND GENOTYPIC ANALYSIS OF A COHORT OF 114 PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA.  
Nicolas Beranger, France
- 17.40 - 17.50** BOARD NO 38: PS 7.2 – CUMULATIVE META-ANALYSIS OF LOW MOLECULAR WEIGHT HEPARIN'S ANTITUMORAL EFFECT: TOWARD THE DISAPPEARANCE OF THE TREATMENT EFFECT.  
Edouard Ollier, France
- 17.50 - 18.00** BOARD NO 39: PS 7.3 – ESTIMATED CARDIORESPIRATORY FITNESS AND FUTURE RISK OF VENOUS THROMBOEMBOLISM IN THE GENERAL POPULATION.  
Line Holtet Evensen, Norway
- 18.00 - 18.10** BOARD NO 40: PS 7.4 – SYNCOPE IS SIGNIFICANT PREDICTOR OF 30-DAY MORTALITY IN FEMALE PULMONARY EMBOLISM PATIENTS.  
Boris Dzudovic, Serbia
- 18.10 - 18.20** BOARD NO 41: PS 7.5 – PULMONARY EMBOLI LOCALIZATION - IMPACT ON CLINICAL PRESENTATION AND CASE FATALITY RATE: A SWEDISH CROSS-SECTIONAL STUDY FROM EMERGENCY DEPARTMENT VISITS.  
Phillip Smith, Sweden
- 18.20 - 18.30** BOARD NO 42: PS 7.6 – VENOUS THROMBOEMBOLISM RISK ASSESSMENT IN 936 WOMEN OF REPRODUCTIVE AGE FROM FAMILIES WITH THROMBOPHILIA: SUB ANALYSIS OF THE MARFAST COHORT.  
Pierre Suchon, France

Thursday 25 October

**17.30 - 18.30**

**Hall: Poster Sessions Area**

## I Clotting 4

- 17.30 - 17.40** BOARD NO 43: PS 8.1 – DEVELOPMENT OF A PROTHROMBINASE-BASED ASSAY TO MEASURE THE SUSCEPTIBILITY OF FACTOR V VARIANTS TO INHIBITION BY TFPI .  
Peter van Doorn, The Netherlands
- 17.40 - 17.50** BOARD NO 44: PS 8.2 – CLINICAL AND LABORATORY CHARACTERISTICS OF TYPE IIHBS ANTITHROMBIN DEFICIENCY; PREVALENCE OF ANTITHROMBIN BUDAPEST 3 MUTATION AMONG DIFFERENT PATIENTS GROUPS AND INVESTIGATION OF ITS ORIGIN.  
Zsuzsanna Bereczky, Hungary
- 17.50 - 18.00** BOARD NO 45: PS 8.3 – ABO BLOOD GROUP AND VENOUS THROMBOEMBOLISM RISK: INPUT OF THE MEASUREMENTS OF PLASMATIC A AND B GLYCOSYLTRANSFERASE ACTIVITIES.  
Manal Ibrahim-Kosta, France
- 18.00 - 18.10** BOARD NO 46: PS 8.4 – PLASMA MIRNAS EXPRESSION AS MARKERS FOR CARDIOVASCULAR EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION.  
Constantino Martínez, Spain
- 18.10 - 18.20** BOARD NO 47: PS 8.5 – PLASMA LEVELS OF PROCOAGULANT PHOSPHOLIPIDS (PPL) ARE ASSOCIATED WITH FUTURE RISK OF INCIDENT VENOUS THROMBOEMBOLISM.  
Cathrine Ramberg, Norway
- 18.20 - 18.30** BOARD NO 48: PS 8.6 – MEASURING CIRCULATING FXIA TO ASSESS ELEVATED FXIA AS RISK FACTOR FOR THROMBOSIS.  
Stan van der Beelen, The Netherlands

Thursday 25 October

**17.30 - 18.30**

**Hall: Poster Sessions Area**

## I Platelets 1

- 17.30 - 17.40** BOARD NO 49: PS 9.1 – IMMUNE THROMBOCYTOPENIA (ITP) IS ASSOCIATED WITH A HIGH DISEASE BURDEN AND HAS A NEGATIVE IMPACT ON PATIENT-REPORTED QUALITY OF LIFE AND PRODUCTIVITY: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH).  
James Bussel, United States of America
- 17.40 - 17.50** BOARD NO 50: PS 9.2 – HYPERSENSITIVE PLATELET SUBPOPULATIONS DETERMINE COLLECTIVE BEHAVIOUR: RESULTS FROM A STUDY OF SINGLE PLATELET FUNCTION USING DROPLET MICROFLUIDICS.  
Maaike Jongen, United Kingdom
- 17.50 - 18.00** BOARD NO 51: PS 9.3 – ASPIRIN THERAPY REDUCES EMBOLIC EVENTS IN PATIENTS WITH INFECTIVE ENDOCARDITIS.  
Laurence Camoin, France
- 18.00 - 18.10** BOARD NO 52: PS 9.4 – PREDICTIVE FACTORS FOR SUCCESSFUL SPLENECTOMY OUTCOME – SYSTEMATIC REVIEW.  
Mirjana Mitrovic, Serbia
- 18.10 - 18.20** BOARD NO 53: PS 9.5 – STICKY PLATELET SYNDROME - EPIDEMIOLOGICAL AND CLINICAL DATA FROM SLOVAK NATIONAL REGISTRY OF THROMBOPHILIA STATES.  
Jan Staško, Slovakia
- 18.20 - 18.30** BOARD NO 54: PS 9.6 – PLATELET AGGREGATION VARIES BY MICROENVIRONMENT IN WOMEN WITH MYELOPROLIFERATIVE NEOPLASMS.  
Eugene Roitman, Russia

Thursday 25 October

**17.30 - 18.30**

**Hall: Poster Sessions Area**

## I Platelets 2

- 17.30 - 17.40** BOARD NO 55: PS 10.1 – IMMATURE PLATELET FRACTION (IPF): A SURROGATE MARKER OF MEAN PLATELET VOLUME (MPV) IN HEREDITARY MACROTHROMBOCYTOPENIA?  
Anne Bauters, France
- 17.40 - 17.50** BOARD NO 56: PS 10.2 – FLOW CYTOMETRY-BASED PLATELET FUNCTION TESTING FOR ASSESSING PLATELET REACTIVITY IN INHERITED AND ACQUIRED PLATELET DYSFUNCTION.  
Anastasia Ignatova, Russia
- 17.50 - 18.00** BOARD NO 57: PS 10.3 – DISAGREGIN: A PLATELET AGGREGATION INHIBITOR FROM THE TICK ORNITHODOROS MOUBATA.  
Danique van den Kerkhof, The Netherlands
- 18.00 - 18.10** BOARD NO 58: PS 10.4 – PLATELET PN-1 REGULATES CLOT STRUCTURE AND RETRACTION.  
Yacine Boulaftali, France
- 18.10 - 18.20** BOARD NO 59: PS 10.5 – PROCOAGULANT ACTIVITY OF MICROPARTICLES FROM STROKE AND MIMICS PATIENTS ON ENDOTHELIAL CELLS.  
Véronique Ollivier, France
- 18.20 - 18.30** BOARD NO 60: PS 10.6 – IS LABORATORY TESTING FOR HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) REQUESTED AFTER THE USE OF 4TS SCORE SYSTEM? A REVIEW.  
Marcos Sousa, Portugal
- 19.15 - 00.00** **Congress dinner**  
Location: Les Grandes Tables at Friche La Belle de Mai (offsite)  
Busses will depart at 18:45 from Palais des Congrès - Marseille Chanot (main entrance)

## Notes

[illegible]

# Programme Day 3 Friday 26 October

- Plenary Session
- Bleeding
- Clotting
- Platelets
- Vessel Wall
- State of the Art
- Science, fast and furious
- French sessions
- Other Sessions
- Special Symposium

	Auditorium	Callelongue	Endoume 1	Endoume 2
08:00 - 08:25	How to . . .		Meet the expert	
08:25 - 08:50	How to . . .		Meet the expert	
08:50 - 09:00		Short break		
09:00 - 10:00	Inherited bleeding disorders	Thrombosis biomarkers	Vessel wall	Pediatric haemostasis
10:00 - 10:30		Coffee break & poster viewing		
10:30 - 11:00	State of the Art Mechanisms of thrombosis associated with cancer	State of the Art Platelet function and response to aspirin in patients with essential thrombocythemia		
11:00 - 11:30	State of the Art Cancer and thrombosis	State of the Art Stroke prevention in atrial fibrillation		
11:30 - 12:30	Science, fast and furious			
12:30 - 13:30		Lunch break & Sport Activity (see page 4)		
13:30 - 14:30	Plenary From Bacterial Host Defense to a New Mechanism of Autoimmunity - Lessons Learned from HIT			
14:30 - 15:00	Closing & ECITH 2019			

Friday 26 October

**08.00 - 08.25**

**Ground Floor**

## **| How-to & Meet the expert**

**08.25 - 08.50**

**Ground Floor**

## **| How-to & Meet the expert**

**08.50 - 09.00**

**Short break**

**09.00 - 10.00**

**Hall: Auditorium**

## **| Oral Communications: Inherited Bleeding Disorders**

**09.00 - 09.15**

OS 13.1 – IMPROVED SURVIVAL OF PATIENTS WITH HAEMOPHILIA IN THE NETHERLANDS IN THE 21ST CENTURY: PRELIMINARY RESULTS.

Rory Monahan, The Netherlands

**09.15 - 09.30**

OS 13.2 – MOLECULAR DEFECTS IN THE F7 GENE OF PATIENTS WITH SEVERE FACTOR VII DEFICIENCY IN IRAN.

Tina Shahani, Iran

**09.30 - 09.45**

OS 13.3 – AAV-MEDIATED GENE TRANSFER OF ENGINEERED FACTOR IX FUSION PROTEINS DOES NOT INCREASE FACTOR IX PLASMA LEVEL OVERTIME IN MICE.

Sandra Le Quellec, France

**09.45 - 10.00**

OS 13.4 – SEVERE POSTPARTUM HEMORRHAGE AS A FIRST PRESENTING SYMPTOM OF A BLEEDING DISORDER.

Caroline Veen, The Netherlands



Friday 26 October

**09.00 - 10.00**

**Hall: Callelongue**

## I Thrombosis Biomarkers

- 09.00 - 09.15** OS 14.1 – IDENTIFICATION OF ENDOTHELIAL DERIVED PLASMA BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR DISEASE RISK FACTORS.  
Maria Jesus Iglesias, Sweden
- 09.15 - 09.30** OS 14.2 – PLASMA LEVELS OF GROWTH DIFFERENTIATION FACTOR 15 ARE ASSOCIATED WITH FUTURE RISK OF VENOUS THROMBOEMBOLISM.  
Ellen-Sofie Hansen, Norway
- 09.30 - 09.45** OS 14.3 – THE ROLE OF THROMBIN GENERATION IN CARDIOVASCULAR DISEASE AND MORTALITY – RESULTS FROM THE POPULATION-BASED GUTENBERG HEALTH STUDY.  
Pauline van Paridon, The Netherlands
- 09.45 - 10.00** OS 14.4 – VALIDATION OF PLASMA MARKER CANDIDATES FOR VTE USING AFFINITY AND MASS SPECTROMETRY-BASED PROTEOMICS INDICATE A LINK TO ALTERNATIVE COMPLEMENT PATHWAY.  
Laura Sanchez, Sweden
- 10.00 - 10.30** **Coffee break & poster viewing**

Friday 26 October

**09.00 - 10.00**

**Hall: Endoume 1**

## I Vessel Wall

- 09.00 - 09.15** OS 15.1 – ROLE OF LIGHT DEFICIENCY IN THE DEVELOPMENT OF ATHEROSCLEROSIS AND ATHEROTHROMBOSIS IN MICE.  
Matthias Canault, France
- 09.15 - 09.30** OS 15.2 – MICROVESICLES FROM T CELLS OVEREXPRESS MIR-146B-5P IN HIV-1 INFECTION AND REPRESS ENDOTHELIAL ACTIVATION.  
Aurelie Leroyer, France
- 09.30 - 09.45** OS 15.3 – SPHINGOMYELIN PHOSPHODIESTERASE IN TARGETED TREATMENT OF VASCULAR CALCIFICATION.  
Angelina Pavlic, The Netherlands
- 09.45 - 10.00** OS 15.4 – THE EFFECT OF FACTOR XIII ON THE PROLIFERATION AND MIGRATION OF VASCULAR SMOOTH MUSCLE CELLS.  
László Muszbek, Hungary

Friday 26 October

**09.00 - 10.00**

**Hall: Endoume 2**

## I Paediatric Haemostasis

**09.00 - 09.15**

OS 16.1 – FIBRINOGEN IN PEDIATRIC CRANIOSYNOSTOSIS SURGERY:  
A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.  
Elise J. Huisman, The Netherlands

**09.15 - 09.30**

OS 16.2 – DIAGNOSTIC MARKERS AND PREDICTORS OF NEONATAL IMMUNE  
THROMBOCYTOPENIA. RUSSIAN EXPERIENCE.  
Alexey Mazurov, Russia

**09.30 - 09.45**

OS 16.3 – GENETIC AND IMMUNE HETEROGENEITY IN PEDIATRIC IMMUNE  
THROMBOCYTOPENIA IS ASSOCIATED WITH TREATMENT RESPONSES TO IVIG  
David Schmidt, The Netherlands

**09.45 - 10.00**

OS 16.4 – INCIDENCE AND FEATURES OF THROMBOTIC EVENTS IN CHILDREN  
WITH INHERITED ANTITHROMBIN DEFICIENCY: RETROSPECTIVE ANALYSIS  
OF 968 SUBJECTS WITH ANTITHROMBIN DEFICIENCY FROM 441 UNRELATED  
FAMILIES.  
Belén de la Morena-Barrio, Spain

**10.00 - 10.30**

**Coffee break & poster viewing**

Friday 26 October

**10.30 - 11.30**

**Hall: Auditorium**

## I State of the Art

**10.30 - 11.00**

SOA 3.1 – MECHANISMS OF THROMBOSIS ASSOCIATED WITH CANCER  
Christophe Dubois, France

**11.00 - 11.30**

SOA 4.1 – CANCER AND THROMBOSIS  
Guy Meyer, France

**10.30 - 11.30**

**Hall: Callelongue**

## I State of the Art

**10.30 - 11.00**

SOA 3.2 – PLATELET FUNCTION AND RESPONSE TO ASPIRIN IN PATIENTS WITH  
ESSENTIAL THROMBOCYTHEMIA  
Marco Cattaneo, Italy

**11.00 - 11.30**

SOA 4.2 – STROKE PREVENTION IN ATRIAL FIBRILLATION  
Deirdre Lane, United Kingdom

Friday 26 October

**11.30 - 12.30**

**Hall: Auditorium**

## I Science, fast and furious

**11.30 - 11.45**

SFF 2.1 – NEW CONSTITUTIONAL GATA1 VARIANTS STUDY REVEALS THE CONTRIBUTION OF GATA1 IN MYH10 SILENCING DURING MEGAKARYOPOIESIS.  
Paul Saultier, France

**11.45 - 12.00**

SFF 2.2 – BLOCKADE OF PLATELET GLYCOPROTEIN VI INDUCES INTRATUMORAL HEMORRHAGE AND INCREASES EFFICACY OF CHEMOTHERAPY.  
Julia Volz, Germany

**12.00 - 12.15**

SFF 2.3 – SEEKING SEVERE RENAL FAILURE IN PATIENTS ANTICOAGULATED FOR AN ACUTE VENOUS THROMBOEMBOLISM: DOES THE FORMULA COUNT?  
Judith Catella-Chatron, France

**12.15 - 13.00**

SFF 2.4 – WHOLE F8 AND VWF GENE SEQUENCING USING NEXT-GENERATION SEQUENCING FOR MUTATION-NEGATIVE FRENCH AND CANADIAN HEMOPHILIA A PATIENTS.  
Fanny Lassalle

**12.30 - 13.30**

**Sport activity: Pétanque**

Location: 2nd floor on the terrace of Palais des Congrès - Marseille Chanot. More details on page 4.

**12.30 - 13.30**

**Lunch break**

Friday 26 October

**13.30 - 14.30**

**Hall: Auditorium**

## I Plenary lecture

**13.30 - 14.30**

FROM BACTERIAL HOST DEFENSE TO A NEW MECHANISM OF AUTOIMMUNITY – LESSONS LEARNED FROM HIT  
Andreas Greinacher, Germany

**14.30 - 15.00**

**Closing & ECTH 2019**

Hall: Auditorium

## Notes

[illegible]

## Poster sessions overview

Topic	Poster board numbers
Vessel Wall	No 1 - 6
Bleeding 1	No 7 - 12
Bleeding 2	No 13 - 18
Bleeding 3	No 19 - 24
Clotting 1	No 25 - 30
Clotting 2	No 31 - 36
Clotting 3	No 37 - 42
Clotting 4	No 43 - 48
Platelets 1	No 49 - 54
Platelets 2	No 55 - 60

## I Posters information

### Poster area

All posters are presented per topic in the poster area located on the ground floor. A list of the posters on display can be found on the congress website and in the mobile application. Posters will be on display in the poster area during the congress.

### Poster mounting

Posters can be mounted as of Wednesday 24 October.

- The number of your poster can be found in the (online) Abstract book and the mobile application.
- Posters should be mounted with double sided tape only. Assistance and material for mounting the posters will be available at the poster desk in the poster area.

### Opening hours poster desk:

Wednesday	24 October	07.00 - 18.00 hours
Thursday	25 October	07.30 - 18.30 hours
Friday	26 October	07.30 - 13.30 hours

### Poster session

The poster Session is held on Thursday 25 October from 17.30 to 18.30 hours. All poster authors are kindly requested to be present at their poster during the entire session to showcase their work. All delegates are invited to walk around the poster area to view the posters and to enter into lively and challenging discussions with the poster presenters. Snacks and drinks will be served, please join us.

### Poster material removing

Material should be taken before Friday 26 October at 13.30 hours. Material that has not been taken down by the author(s) by this time will be removed and destroyed.

### Poster view & discussion

Take advantage of the coffee breaks to walk around, chat and discuss any of the 245 posters presented in the below four areas.

Topics	Poster board numbers	Poster numbers
Bleeding	No 61 - 105	No P101 - P148
Clotting	No 106 - 215	No P149 - P263
Platelets	No 216 - 243	No P264 - P292
Vessel Wall	No 244 - 245	No P293 - P294

### Responsibility for poster presentations

The ECTH and the Local Organising Committee do not assume any responsibility for material displayed on the poster boards.

## I Poster view & Discussion

### Bleeding

- P101** A single centre experience on the safety of newly initiated oral anticoagulation therapy for non-valvular atrial fibrillation in adult patients.  
Helen-Cara Younan, United Kingdom
- P102** Anti-prothrombin antibody, case report  
Brigitte Pan-Petes, France
- P103** Bleeding phenotype in cohort of patients with Von Willebrand disease in west Algeria.  
Driss Benlaldj, Algeria
- P104** Identification of Chinese Hospitalized Patients' Risk Profile for Venous Thromboembolism (DissoLVE 2): Factors Affecting Venous Thromboembolism Risk and Prophylaxis in Hospital Care Setting in China.  
Chen Wang, China
- P105** Importance of thrombin generation tests in patients in treatment with DOACs  
Maria Ida Fernandez Rodriguez, Spain
- P106** Hemorrhagic and thrombotic complications in patients with direct action anticoagulants according to the type of drugs.  
Maria Ida Fernandez Rodriguez, Spain
- P107** Extended half-life factor VIII: from biology to patients' management optimization  
Andreas Perrier-Cornet, France
- P108** Development and characterization of neutralizing monoclonal antibodies targeting the direct oral anticoagulant edoxaban.  
Eric Maurer, France
- P109** Acquired von Willebrand syndrome associated with cerebral aneurysm.  
Dominique Desprez, France
- P110** Bariatric surgery in patients with inherited coagulation deficiencies: an experiment in Strasbourg University Hospital.  
Dominique Desprez, France
- P111** A retrospective observational study on patients with moderate/severe (M/S) hemophilia A in France: HEMONIS study - Methodology and Results on the M/S population.  
Thierry Lambert, France
- P112** Study of Coagulation Factor Inhibitors in Patients with Hemophilia in Kermanshah.  
Mehrddad Payandeh, Iran
- P113** Surgical experiment on haemophilia B patients treated by eptacog alpha (rFIXFc) in Strasbourg: about 3 case reports  
Dominique Desprez, France
- P114** Estimating the long-term cost of bleeding events associated with the use of anticoagulant therapy in a European setting: a systematic literature review.  
Elisabeth Reimer, Denmark
- P115** Betrixaban: Impact on routine and specific coagulation assays - A practical laboratory guide.  
Romain Siriez, Belgium
- P116** Improvement of chromogenic anti-Xa assay to measure betrixaban concentration in plasma.  
Romain Siriez, Belgium
- P117** Pharmacokinetic parameters, FVIII consumption and cost of 13 patients with severe haemophilia who have switched from conventional therapy to Efmoroctocog alfa: experience of a French haemophilia centre.  
Claire Flaujac, France
- P118** Standardization and automation of thrombin generation assay: TG on its way to the clinical lab for haemophilia patients.  
David Courtois, France
- P119** Establishment of a thrombin generation threshold in severe haemophilic patients under prophylaxis to further determine an added value of this test in the personalized treatment: a pilot study.  
Nathaniel Moszynski, Belgium
- P120** Primary hemostasis imbalance during ECMO therapy: preliminary study in Rennes hospital.  
Fabienne Nedelec, France
- P124** A new rapid, specific and simple ELISA for VWF- Propeptide  
Hans- Jürgen Kolde, Germany
- P125** Diagnosis strategy of the Von Willebrand disease in the west Algeria: Single center experience.  
Driss Benlaldj, Algeria

- P126** A retrospective observational study on patients with moderate/severe (M/S) hemophilia A in France: HEMONIS study - Results of the Severe population  
Thierry Lambert, France
- P127** An alternative approach for improving factor ix results in hemophilia B patients treated with alprolix®  
Sophie Voisin, France
- P128** Effect of cell saver on haemostasis parameters during cardiopulmonary by-pass surgery  
Agnès Ribes, France
- P129** Which FVIII:C assay for the monitoring of patients with hemophilia undergoing surgery under the cover of FVIII-Fc fusion protein?  
Anne Lienhart, France
- P130** Gastrointestinal Bleeding and Angiodysplasia in von Willebrand Disease: Results from the secondary interim analysis of the French HRQoL Study: WISH-QoL.  
Annie Borel Derlon, France
- P131** Massive Spontaneous Haemothorax in a Hemophilic Child: A rare case report  
Peyman Eshghi, Iran
- P132** Efficacy of escalating method of prophylactic low dose factor treatment in children with severe hemophilia A & B: Sonographic and clinical scoring outcomes  
Peyman Eshghi, Iran
- P133** Management of prostate biopsy and prostate cancer therapy in patients with haemophilia: a retrospective French multicentre study  
Christine Biron-Andreani, France
- P134** Optimisation of the calibration curve for the accurate measurement of low FVIII levels with one-stage FVIII assays  
Dorien Van den Bossche, Belgium
- P135** Usefulness of anti-factor VIII IgG ELISA in acquired hemophilia  
A diagnosis and follow-up  
Albain Chansavang, France
- P136** Uncommon cause of the prolonged bleeding events – case report  
Renata Pizurova, Slovakia
- P137** Successful management of delivery in rare bleeding disorder patients: An 11 year experience  
Fatemeh Malek, Iran
- P138** Emicizumab transforms lifestyle of patients with inhibitor: a qualitative research in haemophilia A  
Thierry Lambert, France
- P139** Palliative management of a giant iliopectoral haemophilic pseudotumour under emicizumab prophylaxis  
Antoine Rauch, France
- P140** Does a variation of +/- 2°C around 37°C in the incubation temperature influence the measurement of FVIII inhibitor titres?  
Amen Allah Nasr, France
- P141** Association of acquired hemophilia A and IgG4-related disease: case report and pathophysiological study  
Emmanuelle Jean- Pierre, France
- P142** Genetic analysis in Slovak family with inherited factor XIII deficiency  
Jana Zolkova, Slovakia
- P143** Can von Willebrand antigen level be able to predict the clinical outcome in patients with severe Hemophilia A at the initial presentation?  
Selin Aytac, Turkey
- P144** Acquired type 3 von Willebrand syndrome associated with splenic marginal zone lymphoma: a case report  
Anna Selmeczi, Hungary
- P145** Prenatal diagnosis of hemophilia a –five years experience  
Nina Ilic, Serbia
- P146** A case of severe acquired factor X deficiency: diagnosis approach and clinical management of a rare bleeding disorder  
Rémy Favre, France
- P147** Impact of extended half-life recombinant factor VIII Fc in consumption of FVIII in Haemophilia patients A with prophylaxis regimen  
Valérie Chamouard, France
- P148** Preliminary study aiming at collecting the opinion of patients and their caregivers about the development of an electronic diary for rare bleeding disorders in France  
Lola Sépot-Boucherit, France



## Clotting

- P149** Thrombinography and fibrinography in geriatric patients over 80 years with atrial fibrillation receiving rivaroxaban, apixaban, or dabigatran  
Geoffrey Foulon, France
- P150** Clinical evaluation and implementation of a second generation assay in immunoturbidimetric method for di-dimer testing in Cameroon  
Abene Nnoma Louis Hervé, Cameroon
- P152** Non-recommended dosing of direct oral anticoagulants in the treatment of acute pulmonary embolism is related to an increased rate of adverse events  
Romain Chopard, France
- P153** Prescription Patterns of Direct Oral Anticoagulants in Pulmonary Embolism: A prospective multicenter multidisciplinary French registry  
Romain Chopard, France
- P154** Extended anticoagulation for the secondary prevention of venous thromboembolic events: an updated network meta-analysis  
Jean-Christophe Lega, France
- P155** Combined thrombophilia: experience in our centre.  
Bianca Díaz Roldán, Spain
- P156** Role of the thrombophilia study in ischemic cryptogenic ictus in the young patient: experience in our centre.  
Bianca Díaz Roldán, Spain
- P157** Changes in renal function in patients with non valvular atrial fibrillation starting an oral anticoagulant  
Alberto Maino, Italy
- P158** Evaluation of the Cobas t711 coagulation analyzer: a single center experience  
Christelle Orlando, Belgium
- P159** Lack of standardization of the anti-factor (F)Xa activity and the anti-FXa-correlated a PTT therapeutic ranges used in monitoring unfractionated heparin treatments  
Pierre Toulon, France
- P160** Monitoring treatments by unfractionated heparin (UFH). Stability of plasma anti-Xa activity for up to 4 hours in citrated tubes  
Pierre Toulon, France
- P161** The use of the age-adjusted D-dimer threshold to exclude pulmonary embolism  
Athanasia Agorasti, Greece
- P163** Fibrinolytic portrait for different thrombotic conditions in women  
Eugene Roitman, Russia
- P164** Significance of the application the therapeutic plasma exchange (TPE) in patients with thrombotic thrombocytopenic purpura (TTP)  
Bratislav Stankovic, Serbia
- P165** Bone Marrow Necrosis in Patient with Antiphospholipid Syndrome: Case Report and Review of Literature  
Nahlah AlGhasham, Saudi Arabia
- P166** Direct oral anticoagulants for treatment of cerebral venous sinus thrombosis  
Marco Capecci, Italy
- P167** Predictors of venous thromboembolism in patients undergoing neurosurgery for glioma  
Marco Capecci, Italy
- P168** High dietary intake of marine n-3 fatty acids is associated with reduced risk of recurrent VTE  
Trond Isaksen, Norway
- P169** Prognostic factors of catheter-related thrombosis (CRT) are different than prognostic factors of VTE in patients with cancer; Data from the ONCOCIP study.  
Laurent Bertolotti, France
- P170** Joint effects of atrial fibrillation and prothrombotic genotypes on the risk of ischemic stroke. The Tromsø Study.  
Erin Mathiesen Hald, Norway
- P171** Joint effects of atrial fibrillation and prothrombotic genotypes on the risk of venous thromboembolism. The Tromsø Study.  
Erin Mathiesen Hald, Norway
- P172** Slow infusion of reduced dose of alteplase decreases 30-day mortality in patients with intermediate-risk pulmonary embolism.  
Slobodan Obradovic, Serbia
- P173** Evaluation of human-sourced lipid interferences on three different D-dimer enhanced latex immunoassays.  
Frédéric Esteve, France

- P174** Health education and clinical-biological monitoring in patients with DOACs and their impact on thrombotic and hemorrhagic complications  
Maria Ida Fernandez Rodriguez, Spain
- P175** Plasma Fibrinogen Level in Sudanese Patients with Type2 Diabetes Mellitus  
Hana Elkhailfa, Sudan
- P176** Prognostic Impact of Non-Compliance with Guidelines-Recommended Treatment of Acute Pulmonary Embolism: Results from a Prospective Multicenter Registry  
Romain Chopard, France
- P177** Thrombotic risk evaluation of factor V Leiden mutation with thrombin generation test: a retrospective study in Rouen University hospital  
Paul Billoir, France
- P178** After One Month Of Treatment With Apixaban Pulmonary Embolism Patients Have Higher Activity Of Coagulation Factor II, As Compared With Patients Treated With Rivaroxaban And Dabigatran  
Boris Dzudovic, Serbia
- P179** Regular physical activity and risk of recurrent venous thromboembolism (VTE) and VTE-related mortality  
Line Holtet Evensen, Norway
- P180** Determination of reference values of factor II and factor X activity levels in our laboratory for the monitoring of vitamin K antagonist therapy  
Stéphanie Désage, France
- P183** Direct comparisons of brain natriuretic peptide and cardiac troponin I for the prediction of thirty-day all-cause death and pulmonary embolism-cause death in patients with acute pulmonary embolism.  
Ljiljana Kos, Bosnia Herzegovina
- P184** Identification of Chinese Hospitalized Patients' Risk Profile for Venous Thromboembolism (DissoIVE 1): a Nationwide, Multi-center, Observational study.  
Li Xiaoying, China
- P185** Real life Spanish cohort of direct oral anticoagulants in patients with atrial fibrillation: refase registry  
Juan Jose Cerezo, Spain
- P186** Direct oral anticoagulants in real life. Experience of a center during the year 2017. MGJ-API-2018-01.  
Gala Anglaia Mendez Navarro, Spain

- P187** Myocardial infarction as a trigger of incident venous thromboembolism: Results from a case-crossover study.  
Joakim Sejrur, Norway
- P188** Joint effects of myocardial infarction and prothrombotic genotypes on the risk of venous thromboembolism: The Tromsø Study  
Joakim Sejrur, Norway
- P189** Determinants and prognostic impact of diagnosis delay in pulmonary embolism  
Celine Goyard, France
- P190** Evaluation of haemostasis perturbations in two mice models of Chronic Kidney Disease  
Camélia Makhoulfi, France
- P191** Attenuation of monocytes induced procoagulant activity on CoCr surfaces with thin films of degradable polar/hydrophobic/ionic polyurethanes  
Audrey Gossart, France
- P192** A new assay to evaluate microvesicle plasmin generation capacity: validation in disease with fibrinolysis imbalance.  
Sylvie Cointe, France
- P193** A simple, inexpensive and robust assay to measure levels of negatively charged phospholipids – a modified PPL assay.  
Cathrine Ramberg, Norway
- P194** Coagulation factors FVIII, FXI, and FXII and outcomes after first ischemic stroke in PROSCIS-B  
Jessica Rohmann, Germany
- P195** Frequency of FV Leiden (R506Q), prothrombin 20210G>A and MTHFR 677C>T variants in a group of pediatric patients with stroke from Serbia  
Jelena Vukajlovic, Serbia
- P196** Management of high-risk pregnant patients on anticoagulant treatment  
Lucia Stanciakova, Slovakia
- P197** Inherited and acquired risk factors of thrombosis – a single-centre experience  
Lucia Stanciakova, Slovakia
- P198** Micro-ribonucleic acid in high-risk pregnancy  
Lucia Stanciakova, Slovakia
- P199** High-risk pregnant women and genetic changes in the expression of deoxyribonucleic acid  
Lucia Stanciakova, Slovakia

- P200** Rationale and update of Hokusai post-VTE study: a follow-up study on long-term outcomes of venous thromboembolism in patients treated with heparin/ edoxaban vs heparin/warfarin  
Ingrid Bistervels, The Netherlands
- P201** Influence of arterial hypertension on different venous thrombosis types  
Biljana Vuckovic, Serbia
- P202** Thrombosis of v.portae and v.lienalis in pregnant woman with thrombophilia – Case study  
Ivana Pesic Stevanovic, Serbia
- P203** International Pediatric Thrombosis Network: advancing the field of pediatric thrombosis  
Heleen van Ommen, The Netherlands
- P204** Coagulopathy and Pregnancy - Overview of Case  
Emilija Kochovska, Macedonia
- P205** Thrombotic events associated with central venous catheter in patients admitted at a Pediatric Intensive Care Unit of Sao Joao University Hospital  
Mariana Ramalho, Portugal
- P206** Acquired Factor XI Inhibitor interfering with the essays of intrinsic pathway factors: a case report  
Kahina Ghemmour Guenounou, Algeria
- P207** Protein C deficiency - a case report  
Tatjana Timova, Macedonia
- P208** Evaluation of thrombotic risk in antithrombin deficiency variant by thrombin generation assay  
Paul Billoir, France
- P209** Interest of IgG and IgM anti-prothrombin autoantibodies in the exploration of anti-phospholipid syndrome: a 5 years retrospective study  
Daniel Bertin, France
- P210** Potential value of magnetic resonance direct thrombus imaging in preventing over diagnosis by compression ultrasound in patients with suspected ipsilateral recurrent deep venous thrombosis  
Gargi Gautam, Sweden
- P211** Molecular and laboratory characteristics of recessive von Willebrand Disease 2N anno 2018  
Jan Jacques Michiels, The Netherlands
- P212** Evaluation of classical and novel von Willebrand factor assays in von Willebrand disease patients  
Jan Jacques Michiels, The Netherlands
- P213** Monitoring argatroban with rotational thromboelastometry: an emergency alternative to activated partial thromboplastin time?  
Corentin Bassi, France
- P214** Joint effects of D-dimer and prothrombotic genotypes on the future risk of incident venous thromboembolism  
Ellen-Sofie Hansen, Norway
- P215** Does in-vitro addition of activated charcoal allow lupus anticoagulant testing with dRVVT in plasma of patients treated with DOAC?: the CAVIAR study  
Virginie Siguret, France
- P216** Interactions between argatroban and vitamin K antagonists on clotting tests (APT and aPTT) and interest of argatroban measuring during perioperative management: case report.  
Sara Boukhilal, France
- P217** Comparison between the standard thrombin generation method and the automated thrombin generation technique  
Marc Arus, Spain
- P218** ABO blood group and factor VIII levels in thrombophilic families  
Maria Ordoñez García, Spain
- P219** Macrophages stimulated in vitro with LPS and ATP produce large IL-18-positive microparticles which can be detected in patients with systemic-onset juvenile idiopathic arthritis  
Richard Bachelier, France
- P220** Removal of DOACs from plasma: performance comparison and pre-analytical considerations of three different devices  
Celine Bouvy, Belgium
- P221** The presence of anti-ADAMTS13 autoantibodies does not change ADAMTS13 antigen levels measured by an in house developed ADAMTS13 antigen  
Elisa Charlotte Dekimpe, Belgium
- P222** A optimized method to measure tissue factor activity on microvesicles.  
Loris Vallier, France

- P223** The effect of lower-leg injury and knee arthroscopy on coagulation factor levels  
Carolina Touw, The Netherlands
- P224** Genomic Variations in the Fibrinolytic cascade and their role in Venous Thrombosis  
Aniket Prabhudesai, India
- P225** Clot waveform analysis: Determination of optimal wavelength to assess the fibrin coagulation process  
Jonathan Evrard, Belgium
- P226** Clot waveform analysis for measuring and quantifying fibrin clot formation  
Jonathan Evrard, Belgium
- P227** The relationship between absorbance and fibrinogen in the clot waveform analysis  
Jonathan Evrard, Belgium
- P228** Clot waveform analysis: Do the reagents of intrinsic, extrinsic and common coagulation pathway interfere with baseline absorbance  
Jonathan Evrard, Belgium
- P229** Towards point-of-care diagnosis of TTP: Detection of anti-ADAMTS13 autoantibodies using FO-SPR technology  
Sara Horta, Belgium
- P231** Caveats in detection of tissue factor  
Bjarne Østerud, Norway
- P232** Microfluidic modeling of thrombolysis: effect of antiplatelet and anticoagulant agents on tissue plasminogen activator-induced fibrinolysis.  
Stephane Loyau, France
- P233** GWAS identifies new risk variants in ADAMTS13/STKLD1 locus for deep venous thrombosis  
Jana-Ch Hegenbarth, Germany
- P234** Bring of the high multiplex Real-time chain polymerase reaction (PCR)  
Soraya Hadjali-Saichi, Algeria
- P235** Immunoglobulins of healthy donors – a source of anti-idiotypic antibodies against anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura (ITTP) patients?  
Kadri Kangro, Belgium
- P236** From autoantibodies to therapeutics: en route to novel treatment for immune TTP  
Bogac Ercig, The Netherlands
- P237** The balance between fibrin clot formation and fibrinolysis may predict cardiovascular events in patients with stable coronary artery disease  
Søs Neergaard-Petersen, Denmark
- P238** Annual cost of clotting factors in patients with severe (SEV) hemophilia A (HA) in France - an ancillary analysis of hemonis study  
Benoit Polack, France
- P239** A rare case of antiphospholipid syndrome-associated middle cerebral artery stenosis in a young patient presenting with moya-moya pattern: a therapeutic challenge for the internist  
Maria Mylona, Greece
- P240** State of the knowledge on the set up of medical compression in patients at high risk of thrombosis  
Valérie Chamouard, France
- P241** Mice Lacking the Novel Thrombosis Susceptibility Gene Slc44a2 Have Normal Hemostasis but an Aberrant Response to Vascular Injury  
Julia Tilburg, The Netherlands
- P242** Mean platelet volume predicts the complications of arteriovenous fistula in hemodialyzed patients  
Guillaume Lano, France
- P243** Role of factor VIII in clot growth and sensitivity to reversible factor Xa inhibitors  
Cornelis Klufft, The Netherlands
- P244** Rheumatoid arthritis closes the gap in hemostatic balance between pre- and postmenopausal women  
Aleksandra Vranic, Serbia
- P245** Thrombin generation is increased in patients with chronic urticaria that associate angioedema  
Álvaro Fernández-Pardo, Spain
- P246** Utility of the Thrombin Generation Test in various clinical phenotypes to predict thrombotic recurrences in cancer patients without anticoagulant treatment  
Álvaro Fernández-Pardo, Spain
- P247** Assessment of hypercoagulable state in patients with preeclampsia using global haemostatic assays  
Violeta Dopsaj, Serbia

- P248** Point-of-care-INR testing: Challenges  
Jurgita Janukonyte, Denmark
- P249** The significance of the fibrinolysis state in cancer patients receiving chemotherapy  
Vladimir Sukhanov, Russia
- P250** Congenital dysfibrinogenemia – a single centre experience  
Vera Geierova, Czech Republic
- P251** The shortened activation peptide of Pseudonaja textilis venom FX abrogates activation by the intrinsic tenase complex  
Geraldine Poenou, The Netherlands
- P252** Measuring Anti-Factor Xa Peak Levels in Pregnant Women Receiving Therapeutic Enoxaparin Dose: A Prospective Observational Study  
Fahad Al-Eidan, Saudi Arabia
- P253** Two mutations in the FGB gene in patients with a quantitative fibrinogen disorder with bleeding and thrombotic phenotype  
Tomas Simurda, Slovakia
- P254** Risk factors, thromboprophylaxis and occurrence of thrombotic events in multiple myeloma patients attending a university hospital.  
Mariana Ramalho, Portugal
- P255** Does addition of three SNPs to the genetic investigation of thrombophilia give better risk prediction in a cohort that was clinically tested after VTE or family history of VTE?  
Maria Farm, Sweden
- P256** Clinical factors associated with PE in patients initially subjected to diagnostic cardiac work up: A Swedish cross-sectional study from over ninety thousand emergency department visits  
Philip Smith, Sweden
- P257** Association of an Afibrinogenemia and a FV Leiden in two patients within the same family.  
Soraya Hadjali-Saichi, Algeria
- P258** The incidence of coagulopathy after adverse reactions to platelet transfusions in pediatric haematology patients  
Olivera Serbic, Serbia
- P259** Overall hemostatic potential and thrombin generation in patients with atrial fibrillation receiving rivaroxaban  
Anica Petkovic, Serbia
- P260** Advanced proteomic approach to identify a specific protein plasma profile associated to venous thromboembolism  
Álvaro Fernández-Pardo, Spain
- P261** Haemostatic disturbances in children with acute leukemia at presentation and during induction therapy-single center experience  
Milena Jovic, Serbia
- P262** Management of intraoperative anticoagulation for cardiopulmonary bypass heart transplantation in a patient with acute heparin-induced thrombocytopenia undergoing heart transplantation.  
Marie Toussaint, France
- P263** Anticoagulant Protein Level Differences Between Young and Elderly Patients with Myocardial Infarction  
Antonijevic Nebojsa, Serbia

## Platelets

- P264** Platelet aggregation induced by serine proteinase isolated from *Vipera lebetina* snake venom: involvement of purinergic signaling pathway  
Amel Kadi-Saci, Algeria
- P265** Does the response to antiplatelet therapy influence the appearance of thromboembolic events in patients with carotid stenosis and eversion endarterectomy-pilot study  
Tina Novakovic, Serbia
- P266** Flavonoid metabolites with antiplatelet effects  
Lenka Applova, Czech Republic
- P267** Biological Evaluation of the Therapeutic Effectiveness of Platelet Antiaggregant in Patients with Coronary Pathology  
Hacene Brouk, Algeria
- P268** Fluoxetine amplifies ticagrelor mediated protection during myocardial reperfusion injury  
Maximilian Mauler, Germany
- P269** Comparison of manual and automated platelet count in patients with low platelets  
Dragana Mili, Serbia
- P270** evaluation of heparin-induced multiple electrode aggregometry method for the diagnosis of heparin-induced thrombocytopenia using 5B9 as a reference hit IGG antibody  
Claire Pouplard, France
- P271** Assessment of light transmission aggregometry on the routine coagulation analyzer Siemens CS-2500 using CE-marked agonists from Hyphen Biomed  
Chloé James, France
- P273** A novel rapid method of platelets and red blood cells permeabilization and staining for flow cytometry analysis.  
Sixtine Faure, France
- P274** Standardisation of platelet sialylation quantification by flow cytometry and reference values in healthy subjects  
Dominique Lasne, France
- P275** Specific features of fluorophore sequestering in platelets allow more precise measurement of calcium concentration in cytosol  
Alexey Martyanov, Russia
- P276** Functional HIT testing based on flow cytometry-our experiences  
Ingrid Skornova, Slovakia
- P277** Contribution of the MAIPA Test in the Biological Exploration of ITP  
Hacene Brouk, Algeria
- P278** Long-term safety and efficacy of eltrombopag in pediatric chronic immune thrombocytopenia (cITP): An extension study of Russian patients previously enrolled in PETIT2  
Elena Donyush, Russia
- P279** Autologous Platelet-Released Growth Factor and sexual dysfunction amendment: A Case series of successful improvement sexual dysfunction after pelvic irradiation  
Saeed Mohammadi, Iran
- P280** Optimised tools for evaluation of platelet function measured by impedance aggregometry  
Anna Schultz-Lebahn, Denmark
- P281** Endothelial activation in acquired thrombotic thrombocytopenic purpura: mechanisms and correlation with disease severity  
Edwige Tellier, France
- P282** Effect of Direct Oral Anticoagulants on platelet reactivity  
Georges Jourdi, France
- P283** Coagulopathy associated with Isolated Traumatic Brain Injury  
Anastasia Baranich, Russia
- P284** Platelet function in preterm neonates  
Alexander Grevsen, Denmark
- P285** No integrin deactivation assessed by fibrinogen binding to platelets was observed during reversible platelet aggregation induced by ADP  
Aleksandra Filkova, Russia
- P286** Modulation of the platelet count by Romiplostim and inhibitors of LIM kinase in genetically-engineered von Willebrand disease type 2B mice: in vivo evaluation of haemostatic efficiency.  
Mathilde Cheptou, France

- P287** Assessment of Platelet Aggregation with Automated Method Among Tunisian Healthy Blood Donors  
Hadeif Skouri, Tunisia
- P288** A novel GATA 1 mutation identified within one French family with thrombocytopenia and microcytosis  
Sophie Bayart, France
- P289** Stormorken-Sjaastad-Langslet syndrome: a new family.  
Sophie Bayart, France
- P290** Imaging P2Y12-inhibited and non-inhibited platelets in the building thrombus under flow in vitro  
Tomas Lindahl, Sweden
- P291** Adipocyte influences megakaryopoiesis: a link with obesity  
Sonia Severin, France
- P292** MicroRNA and hyperaggregability of thrombocytes in sticky platelet syndrome- our first experiences  
Lubica Vadelova, Slovakia

## Vessel Wall


- P293** Validation of a rapid von Willebrand factor propeptide assay  
Muriel Meiring, South Africa
- P294** Effect of plasma components on Staphylococcus aureus adhesion to tissues used for the right ventricular outflow tract (RVOT) revalvulation  
Bartosz Dittkowski, Belgium

# Floor plans




Floor plan

Ground floor




Floor plan  
First floor



Floor plan

Second floor



## Notes

[illegible]



# Special symposia and Partners

## I Acknowledgements

ECTH wishes to express its gratitude to the following sponsors:



# The role of direct oral anticoagulants in cancer-related VTE



Thursday 25 October 2018

12:15–13:15

Auditorium

Palais des Congrès – Marseille Chanot,  
Marseille, France

Chair: Harry Büller, the Netherlands



Daiichi-Sankyo

Passion for Innovation.  
Compassion for Patients.™





**12:15 Welcome and introduction**

Harry Büller, the Netherlands

**12:20 From CLOT to CATCH: LMWH for VTE in cancer patients**

Peter Verhamme, Belgium

**12:35 Challenges of treating cancer related VTE: oncologist perspectives**

Hanno Riess, Germany


**12:50 New standard of care for VTE treatment in cancer patients: are DOACs the answer?**

Cihan Ay, Austria

**13:05 Q&A**

## Objectives of the ECTH Satellite Symposium 2018:

- To discuss challenges of treating cancer-related VTE
- To review emerging evidence of anticoagulation therapy in cancer-related VTE
- To discuss paradigm shift from LMWH to DOAC in cancer-related VTE
- To assess the results of the Hokusai-VTE cancer study and to discuss the implications of the study to the field of cancer and VTE







Driven by  
Our Promise™  
**CSL Behring**



# SYMPOSIUM CSL BEHRING

---

Thursday, October 25<sup>th</sup> 2018

12.15 pm - 13.15 pm  
Room Callelongue

## **Beliefs and attitudes towards pharmacokinetics: from design to practice**

---

**12.15 - 12.20**

### **Welcome and Introduction**

Philippe Nguyen • Reims • France

**12.20 - 12.35**

### **Pharmacokinetics: which reading for which use ?**

Sylvain Goutelle • Lyon • France

**12.35 - 12.50**

### **PK based clinical management: helpful or trendy ?**

Philippe Nguyen • Reims • France

**12.50 - 13.05**

### **Impact of post-translational changes on PK parameters of a recombinant coagulation factor**

Peter Lenting • Le Kremlin-Bicêtre • Paris • France

**13.05 - 13.15**

### **Questions & Answers**

Faculty

### **Closing remarks**

Philippe Nguyen • Reims • France

**CSL Behring**

# **Addressing the needs of individuals with haemophilia A or von Willebrand disease**



**ECTH 2018  
Marseille, France  
Thursday 25<sup>th</sup> October 2018  
12:15 – 13:15  
Location: Room Endoume 1**

This scientific symposium is for healthcare professionals only

**octapharma®**

# DISCUSSION AGENDA

TIME	SPEAKER	DISCUSSION TITLE
12:15	<b>Yesim Dargaud</b>	Welcome and introduction by the Chair
12:20	<b>Carmen Escuriola Ettingshausen</b>	Going further with simoctocog alfa: Addressing the individual needs of people with haemophilia A
12:40	<b>Christoph Kannicht</b>	Taking FVIII into the future: The development of a subcutaneous recombinant human FVIII for the treatment of haemophilia A
12:55	<b>Erik Berntorp</b>	Real-world experience with a 1:1 VWF/FVIII concentrate in patients with von Willebrand disease
13:10	<b>Yesim Dargaud</b>	Discussion and Conclusions



# JOINT HEALTH IN HAEMOPHILIA PATIENTS : TOWARDS A NEW ERA ?

---

Chairman  
**Pr Hervé CHAMBOST**  
Marseille

**SYMPOSIUM**  
**OCTOBER 25<sup>TH</sup>, 2018**  
12H15 AM • 13H15 PM

Palais des Congrès  
Hall : Endoume 2  
Parc Chanot  
Rond-Point du Prado  
13009 Marseille



**ECTH2018**  
European Congress on  
Thrombosis and Haemostasis  
Marseille, France





# REDÉFINIR LA PROTECTION\* POUR TOUS VOS PATIENTS HÉMOPHILES A

## Facteur VIII humain recombinant à demi-vie prolongée



**INDICATIONS :** Traitement et prophylaxie des épisodes hémorragiques chez les patients atteints d'hémophilie A (déficit congénital en FVIII). ELOCTA® est indiqué dans toutes les tranches d'âge<sup>(1)</sup>.

**PLACE DANS LA STRATÉGIE THÉRAPEUTIQUE :** ELOCTA® fait partie des concentrés de facteur VIII de première intention dans le traitement et la prophylaxie des épisodes hémorragiques de l'hémophilie A<sup>(2)</sup>.

\* définie comme le temps passé avec un taux résiduel de FVIII > 1% (1UI/dL)<sup>(3,4)</sup>.

▼ Ce médicament fait l'objet d'une surveillance supplémentaire qui permettra l'identification rapide de nouvelles informations relatives à la sécurité. Les professionnels de la santé déclarent tout effet indésirable suspecté.

Le RCP d'Elocta® est disponible sur le site internet de l'Agence européenne des médicaments <http://www.ema.europa.eu>.

Pour toute demande d'information médicale, veuillez nous envoyer un email à [medinfo.fr@sobi.com](mailto:medinfo.fr@sobi.com)

1/ Résumé des Caractéristiques du Produit en vigueur

2/ Avis de la Commission de la Transparence en date du 17/02/2016

3/ Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. PW Collins et al. J Thromb Haemost 2010; 8: 269–75.

4/ New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins. MV Ragni. Drugs. 2015 Sep;75(14):1587–600.

Sobi (Swedish Orphan Biovitrum) - Siège social France  
14 Place Marie-Jeanne Bassot - 92300 Levallois-Perret  
Tél : +33 (0)1 85 78 03 40  
[www.sobifrance.fr](http://www.sobifrance.fr)

 **sobi**  
Pioneer in Rare Diseases

Réf : 006ELO-FR-2018 - VISA ANSM 18/04/64440763/PM/003 - Date : Avril 2018

 **ELOCTA®** ▼  
Efmoctocog alfa

WE HAVE SEEN SHARING,  
HESITATION, HOPE, PAIN,  
DOUBTS, PRIDE, MEETINGS,  
DETERMINATION, FEAR, OPTIMISM,  
SMILES, DARING, COURAGE, CONFIDENCE,  
WORRIES, PERSEVERANCE,



AFTER ALL,  
IN THE HAEMOPHILIA  
COMMUNITY,  
THERE IS JUST ONE THING  
THAT WE HAVE NOT SEEN.  
GIVING UP.

To all with haemophilia, all their friends and family, to the care teams, researchers, patient associations, to all those fighting haemophilia from near or far, we want to say *Thank you*

Thank you, as you give and prove the best of yourselves every day.  
You are writing your stories every day without giving up.  
**Now, this story goes on and we are proud to write it with you.**

Agence FMAud - D-18/00451 - Etabli en juillet 2018





Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions.

We seek to push boundaries through discovering and delivering new possibilities for patient communities who often have few or no other champions. Relentlessly on the edge of what's next, we are serial innovators with a diverse pipeline offering fresh thinking and new hope. Serving patients and partnering with healthcare communities in over 100 countries, we strive to be part of the entire patient journey to enable earlier diagnosis, raise standards of care, accelerate access to treatment, and support patients. Our diverse portfolio of therapeutic areas includes Immunology, Hematology, Genetic Diseases, Neuroscience, Internal Medicine, and Ophthalmics.

Championing patients is our call to action - it brings the opportunity - and responsibility - to change people's lives.

[www.shire.com](http://www.shire.com)  
<https://jobs.shire.com>







Innovation



Automated  
System



Complete  
Solution



Standardisation

## Bring Haemostasis to light

Thrombin Generation dedicated  
to the Clinical Lab



At the Heart of Haemostasis

Diagnostica Stago S.A.S.  
RCS Nanterre B305 151 409  
3, allée Thérèse  
92600 Asnières sur Seine  
France  
Ph.: +33 (0)1 46 88 20 20  
Fax: +33 (0)1 47 91 08 91  
webmaster@stago.com  
www.stago.com





EXPLORE  
THE POSSIBILITIES  
WITH CONFIDENCE



**KOVALTRY® has him covered**

- **An enhanced rFVIII** that you can rely on for your pediatric patients<sup>5,6</sup>
- **Consistent PK coverage** across age groups<sup>2,3</sup>
- **Bleed control** that covers him throughout childhood<sup>2</sup>

**KOVALTRY®** 250/500/1000/2000/3000 IU powder and solvent for solution for intravenous injection.  
**Composition:** Active ingredient: recombinant human coagulation factor VIII, 250/500/1000/2000/3000 IU/vial.  
**Excipients:** sucrose, histidine, glycine, sodium chloride, calcium chloride and polysorbate 80.  
**Therapeutic indications:** Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). KOVALTRY® can be used for all age groups. **Contraindications:** Hypersensitivity to the active substance or to any of the excipients. Known allergic reactions to mouse or hamster proteins. **Warnings and Precautions:** Allergic type hypersensitivity reactions are possible. If symptoms of hypersensitivity occur, patients should be advised to discontinue medicinal product immediately and contact their physician. The formation of neutralizing antibodies (inhibitors) to FVIII is a known complication in the management of individuals with haemophilia A. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all Factor VIII products. Carefully monitor patients for the development of Factor VIII inhibitors, using appropriate clinical observations and laboratory tests. Haemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-haemophilic patients when clotting has been normalized by treatment with FVIII.

PK-pharmacokinetic: rFVIII-recombinant factor VIII.

**References:** 1. Garger S, Severs J, Regan L, et al. BAY 81-8973, a full-length recombinant factor VIII: manufacturing process and product characteristics. Haemophilia. 2017;23(2):e67-e78. 2. KOVALTRY® [Summary of Product Characteristics]. Leverkusen, Germany: Bayer AG; 2017. 3. Liang R, Kenet G, Mancuso ME, et al, on behalf of the investigators of the LEOPOLD Kids Trial. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial. Haemophilia. 2016;22(3):354-360. 4. Saenen K, Laksara S, Odenburg J, et al. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial. Haemophilia. 2014;20(5):706-712. 5. Enriquez MM, Thrift J, Garger S, Kattorie Y. BAY 81-8973, a full-length recombinant factor VIII: human heat shock protein 70 improves the manufacturing process without affecting clinical safety. Protein Expr Purif. 2016;127:111-115.

© 2018 Bayer AG. All rights reserved. Bayer, the Bayer Cross, and KOVALTRY are registered trademarks of Bayer. G.MKT.SM.HEM.06.2017.1459 PP-KOG-ALL-0006-1

If a central venous access device (CVAD) is required, risk of CVAD-related complications including local infections, bacteraemia and catheter site thrombosis should be considered. KOVALTRY® should be used during pregnancy and breast-feeding only if clearly indicated. **Undesirable effects: common:** lymphadenopathy, palpitation, sinus tachycardia, abdominal pain, abdominal discomfort, dyspepsia, pyrexia, chest discomfort, injection site reactions (incl. injection site extravasation, hematoma, infusion site pain, pruritus, swelling), headache, dizziness, insomnia, pruritus, rash (rash, rash erythematous, rash pruritic), dermatitis allergic; **uncommon:** hypersensitivity, dysgeusia, urticaria, flushing. **Medicinal product subject to medical prescription.**

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

**Date:** 04/17

**Marketing Authorisation Holder:** Bayer AG, 51368 Leverkusen, Germany.

**For important safety and use information, please see summary of product characteristics or country-specific prescribing information.**



**KEDRION**  
BIOPHARMA

Keep Life Flowing

**Kedrion Biopharma** develops, produces and distributes plasma-derived products for use in treating and preventing serious diseases and conditions such as Hemophilia, Primary Immunodeficiencies and Rh sensitization, which can lead to Hemolytic Disease of the Fetus and Newborn. We act as a bridge between donors and patients by turning plasma into life-saving therapies to serve patients all over the world.

[kedrion.com](http://kedrion.com)



## A BIOPHARMACEUTICAL GROUP COMMITTED TO THE LIFE

OF HUNDREDS OF THOUSANDS OF PATIENTS SUFFERING FROM SERIOUS AND OFTEN RARE DISEASES WHO ARE TREATED EACH YEAR WITH OUR BIOPHARMACEUTICALS.

The LFB Group specializes in biopharmaceuticals: plasma-derived medicinal products, recombinant proteins, monoclonal antibodies and advanced therapies.

The LFB Group manufactures its biological medicines in 5 bioproduction plants – 4 of which are in France – and markets its products in almost 60 countries.

[www.groupe-lfb.com](http://www.groupe-lfb.com)

Follow us on social networks



Expect the best  
Haemostasis assays powered by Sysmex



Come and visit us at our booth in the network area to learn about our innovative solutions:

- Sysmex CS-Series
- Automated platelet aggregation assays
- DOACs assays
- Haemophilia management and more!

[www.sysmex-europe.com](http://www.sysmex-europe.com) · [www.sysmex.fr](http://www.sysmex.fr) · [www.hyphen-biomed.com](http://www.hyphen-biomed.com)

# Automating Complex Assays.

The wait is over.



**ACL AcuStar**  
HEMOSTASIS TESTING SYSTEM

## A breakthrough in specialty testing. It's about time. And accuracy.

The **ACL AcuStar** brings full automation to specialty Hemostasis testing that, until now, has required time-consuming manual processes. Advanced chemiluminescent technology automates and standardizes highly specialized assays and enhances routine testing. The ACL AcuStar is changing today's hemostasis lab, combining testing accuracy and efficiency in ways never before possible. The result is greater savings and no waiting.

**Automated specialty testing is here. Break through with IL.**

For more information, please contact your local Werfen sales representative/distributor or visit [www.werfen.com](http://www.werfen.com)

©2017 Instrumentation Laboratory. All rights reserved.

HEMOSTASIS INNOVATION IS HERE. ►

New: HemoIL® AcuStar  
ADAMTS13 Activity  
assay-25T available in 2019

### ACL AcuStar HemosIL® Test Menu

Comprehensive line of high-performance chemiluminescent assays, with more in development.

D-Dimer	aCL IgG	VWF:RCo*
HIT-IgG	aCL IgM	VWF:Ag*
HIT-Ab (PF4+)	aβ <sub>2</sub> GPI IgG	VWF:CB*
HIT-Ab (PF4+)	aβ <sub>2</sub> GPI IgM	

\*Not FDA 510(k)-cleared. Not saleable in the US.

 **Instrumentation  
Laboratory**  
A Werfen Company

## Notes

[illegible]





Let's meet again  
in **Glasgow**



**ECTH 2019**  
European Congress on  
Thrombosis and Haemostasis  
**Glasgow, United Kingdom**  
2 - 4 October